1

Medical Cannabis Amendments

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Evan J. Vickers

]	LONG TITLE
(General Description:
	This bill amends provisions related to medical cannabis.
]	Highlighted Provisions:
	This bill:
	 amends surveillance requirements;
	 allows the Cannabis Production Establishment and Pharmacy Licensing Advisory Board
((licensing board) to renew or approve medical cannabis courier licenses;
	 allows the licensing board to renew licenses as necessary instead of only in December;
	 amends reporting requirements;
	 removes the requirement that pharmacy and courier agent registration cards include the
8	agent's employer on the card;
	 allows for medical cannabis cardholders to bring their own opaque bag or box to transport
r	nedical cannabis from the pharmacy;
	 requires medical cannabis pharmacies and couriers to report a change in ownership at
1	east 45 days before the change occurs;
	 requires qualified medical provider employee proxies to complete an annual course on
ł	nealth information privacy;
	 removes certain information from the medical cannabis card;
	 aligns continuing education provisions of qualified medical providers and pharmacy
ľ	nedical providers; and
	 makes technical and conforming changes.
Ι	Money Appropriated in this Bill:
	None
(Other Special Clauses:
	None
l	Utah Code Sections Affected:
ł	AMENDS:
	4-41a-102, as last amended by Laws of Utah 2024, Chapters 217, 238 and 240

32 4-41a-103, as last amended by Laws of Utah 2023, Chapter 327 33 4-41a-201, as last amended by Laws of Utah 2024, Chapter 217 34 4-41a-201.1, as last amended by Laws of Utah 2024, Chapter 217 4-41a-401, as last amended by Laws of Utah 2024, Chapter 217 35 36 4-41a-801, as renumbered and amended by Laws of Utah 2018, Third Special Session, 37 Chapter 1 38 4-41a-802, as last amended by Laws of Utah 2024, Chapter 217 39 **4-41a-1001**, as last amended by Laws of Utah 2024, Chapters 217, 238 and 240 40 4-41a-1101, as last amended by Laws of Utah 2024, Chapter 217 41 4-41a-1102, as last amended by Laws of Utah 2024, Chapters 217, 240 42 **4-41a-1106**, as last amended by Laws of Utah 2024, Chapter 217 43 4-41a-1202, as last amended by Laws of Utah 2024, Chapters 217, 240 44 4-41a-1204, as last amended by Laws of Utah 2023, Chapter 317 and renumbered and 45 amended by Laws of Utah 2023, Chapters 273, 307 and last amended by Coordination Clause, 46 Laws of Utah 2023, Chapter 307 47 26B-1-435, as last amended by Laws of Utah 2024, Chapters 238, 240 48 **26B-4-202**, as last amended by Laws of Utah 2024, Chapters 217, 240 49 26B-4-204, as last amended by Laws of Utah 2024, Chapter 217 50 **26B-4-213**, as last amended by Laws of Utah 2024, Chapters 217, 240 51 26B-4-219, as last amended by Laws of Utah 2024, Chapter 507 26B-4-222, as last amended by Laws of Utah 2024, Chapter 240 52 53 54 *Be it enacted by the Legislature of the state of Utah:* 55 Section 1. Section 4-41a-102 is amended to read: 56 4-41a-102. Definitions. 57 As used in this chapter: 58 (1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be 59 injurious to health, including: 60 (a) pesticides; 61 (b) heavy metals; 62 (c) solvents; 63 (d) microbial life; 64 (e) artificially derived cannabinoid; 65 (f) toxins; or

66	(g) foreign matter.
67	(2) "Advertise" or "advertising" means information provided by a person in any medium:
68	(a) to the public; and
69	(b) that is not age restricted to an individual who is at least 21 years old.
70	(3) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
71	Section 26B-1-435.
72	(4)(a) "Anticompetitive business practice" [means any practice that reduces the amount
73	of competition in the medical cannabis market that would be considered an attempt to
74	monopolize, as defined in Section 76-10-3103] means any practice that is an illegal
75	anticompetitive activity under Section 76-10-3104.
76	(b) "Anticompetitive business practice" may include:
77	(i) agreements that may be considered unreasonable when competitors interact to the
78	extent that they are:
79	(A) no longer acting independently; or
80	(B) when collaborating are able to wield market power together;
81	(ii) monopolizing or attempting to monopolize trade by:
82	(A) acting to maintain or acquire a dominant position in the market; or
83	(B) preventing new entry into the market; or
84	(iii) other conduct outlined in rule.
85	(5)(a) "Artificially derived cannabinoid" means a chemical substance that is created by
86	a chemical reaction that changes the molecular structure of any chemical substance
87	derived from the cannabis plant.
88	(b) "Artificially derived cannabinoid" does not include:
89	(i) a naturally occurring chemical substance that is separated from the cannabis plant
90	by a chemical or mechanical extraction process; or
91	(ii) a cannabinoid that is produced by decarboxylation from a naturally occurring
92	cannabinoid acid without the use of a chemical catalyst.
93	(6) "Cannabis Research Review Board" means the Cannabis Research Review Board
94	created in Section 26B-1-420.
95	(7) "Cannabis" means the same as that term is defined in Section 26B-4-201.
96	(8) "Cannabis concentrate" means:
97	(a) the product of any chemical or physical process applied to naturally occurring
98	biomass that concentrates or isolates the cannabinoids contained in the biomass; and
99	(b) any amount of a natural cannabinoid or artificially derived cannabinoid in an

100	artificially derived cannabinoid's purified state.
101	(9) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is not
102	intended to be sold as a cannabis plant product.
103	(10) "Cannabis cultivation facility" means a person that:
104	(a) possesses cannabis;
105	(b) grows or intends to grow cannabis; and
106	(c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis
107	processing facility, or a medical cannabis research licensee.
108	(11) "Cannabis cultivation facility agent" means an individual who
109	holds a valid cannabis production establishment agent registration card with a cannabis
110	cultivation facility designation.
111	(12) "Cannabis derivative product" means a product made using cannabis concentrate.
112	(13) "Cannabis plant product" means any portion of a cannabis plant intended to be sold in
113	a form that is recognizable as a portion of a cannabis plant.
114	(14) "Cannabis processing facility" means a person that:
115	(a) acquires or intends to acquire cannabis from a cannabis production establishment;
116	(b) possesses cannabis with the intent to manufacture a cannabis product;
117	(c) manufactures or intends to manufacture a cannabis product from unprocessed
118	cannabis or a cannabis extract; and
119	(d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a
120	medical cannabis research licensee.
121	(15) "Cannabis processing facility agent" means an individual who
122	holds a valid cannabis production establishment agent registration card with a cannabis
123	processing facility designation.
124	(16) "Cannabis product" means the same as that term is defined in Section 26B-4-201.
125	(17) "Cannabis production establishment" means a cannabis cultivation facility, a cannabis
126	processing facility, or an independent cannabis testing laboratory.
127	(18) "Cannabis production establishment agent" means a cannabis cultivation facility agent,
128	a cannabis processing facility agent, or an independent cannabis testing laboratory agent.
129	(19) "Cannabis production establishment agent registration card" means a registration card
130	that the department issues that:
131	(a) authorizes an individual to act as a cannabis production establishment agent; and
132	(b) designates the type of cannabis production establishment for which an individual is
133	authorized to act as an agent.

134 (20) "Closed-door medical cannabis pharmacy" means a facility operated by a home 135 delivery medical cannabis pharmacy for delivering cannabis or a medical cannabis 136 product. 137 (21) "Community location" means a public or private elementary or secondary school, a 138 church, a public library, a public playground, or a public park. 139 (22) "Cultivation space" means, quantified in square feet, the horizontal area in which a 140 cannabis cultivation facility cultivates cannabis, including each level of horizontal area 141 if the cannabis cultivation facility hangs, suspends, stacks, or otherwise positions plants 142 above other plants in multiple levels. 143 (23) "Delivery address" means: 144 (a) for a medical cannabis cardholder who is not a facility: 145 (i) the medical cannabis cardholder's home address; or 146 (ii) an address designated by the medical cannabis cardholder that: 147 (A) is the medical cannabis cardholder's workplace; and 148 (B) is not a community location; or (b) for a medical cannabis cardholder that is a facility, the facility's address. 149 150 (24) "Department" means the Department of Agriculture and Food. 151 (25) "Family member" means a parent, step-parent, spouse, child, sibling, step-sibling, 152 uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law, brother-in-law, 153 sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild. 154 (26) "Government issued photo identification" means the same as that term is defined in 155 Section 26B-4-201, including expired identification in accordance with Section 156 26B-4-244. 157 (27) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that 158 the department authorizes, as part of the pharmacy's license, to deliver medical cannabis 159 shipments to a delivery address to fulfill electronic orders that the state central patient 160 portal facilitates. 161 (28)(a) "Independent cannabis testing laboratory" means a person that: 162 (i) conducts a chemical or other analysis of cannabis or a cannabis product; or 163 (ii) acquires, possesses, and transports cannabis or a cannabis product with the intent 164 to conduct a chemical or other analysis of the cannabis or cannabis product. 165 (b) "Independent cannabis testing laboratory" includes a laboratory that the department or a research university operates in accordance with Subsection 4-41a-201(14). 166 167 (29) "Independent cannabis testing laboratory agent" means an individual who

168	holds a valid cannabis production establishment agent registration card with an
169	independent cannabis testing laboratory designation.
170	(30) "Inventory control system" means a system described in Section 4-41a-103.
171	(31) "Licensing board" or "board" means the Cannabis Production Establishment and
172	Pharmacy Licensing Advisory Board created in Section 4-41a-201.1.
173	(32) "Medical cannabis" means the same as that term is defined in Section 26B-4-201.
174	(33) "Medical cannabis card" means the same as that term is defined in Section 26B-4-201.
175	(34) "Medical cannabis courier" means a courier that:
176	(a) the department licenses in accordance with Section 4-41a-1201; and
177	(b) contracts with a home delivery medical cannabis pharmacy to deliver medical
178	cannabis shipments to fulfill electronic orders that the state central patient portal
179	facilitates.
180	(35) "Medical cannabis courier agent" means an individual who:
181	(a) is an employee of a medical cannabis courier; and
182	(b) who holds a valid medical cannabis courier agent registration card.
183	(36) "Medical cannabis pharmacy" means the same as that term is defined in Section
184	26B-4-201.
185	(37) "Medical cannabis pharmacy agent" means the same as that term is defined in Section
186	26B-4-201.
187	(38) "Medical cannabis research license" means a license that the department issues to a
188	research university for the purpose of obtaining and possessing medical cannabis for
189	academic research.
190	(39) "Medical cannabis research licensee" means a research university that the department
191	licenses to obtain and possess medical cannabis for academic research, in accordance
192	with Section 4-41a-901.
193	(40) "Medical cannabis shipment" means a shipment of medical cannabis that a home
194	delivery medical cannabis pharmacy or a medical cannabis courier delivers to a delivery
195	address to fulfill an electronic medical cannabis order that the state central patient portal
196	facilitates.
197	(41) "Medical cannabis treatment" means the same as that term is defined in Section
198	26B-4-201.
199	(42) "Medicinal dosage form" means the same as that term is defined in Section 26B-4-201.
200	(43) "Pharmacy ownership limit" means an amount equal to 30% of the total number of
201	medical cannabis pharmacy licenses issued by the department rounded down to the

- 202 nearest whole number. 203 (44) "Pharmacy medical provider" means the same as that term is defined in Section 204 26B-4-201. 205 (45) "Qualified medical provider" means the same as that term is defined in Section 206 26B-4-201. 207 (46) "Qualified Production Enterprise Fund" means the fund created in Section 4-41a-104. 208 (47) "Recommending medical provider" means the same as that term is defined in Section 209 26B-4-201. 210 (48) "Research university" means the same as that term is defined in Section 53B-7-702 and 211 a private, nonprofit college or university in the state that: 212 (a) is accredited by the Northwest Commission on Colleges and Universities; 213 (b) grants doctoral degrees; and 214 (c) has a laboratory containing or a program researching a schedule I controlled 215 substance described in Section 58-37-4. 216 (49) "State electronic verification system" means the system described in Section 26B-4-202. 217 (50) "Targeted marketing" means the promotion of a cannabis product, medical cannabis 218 brand, or a medical cannabis device using any of the following methods: 219 (a) electronic communication to an individual who is at least 21 years old and has 220 requested to receive promotional information; 221 (b) an in-person marketing event that is: 222 (i) held inside a medical cannabis pharmacy; and 223 (ii) in an area where only a medical cannabis cardholder may access the event; 224 (c) other marketing material that is physically available or digitally displayed in a 225 medical cannabis pharmacy; or 226 (d) a leaflet a medical cannabis pharmacy places in the opaque package or box that is 227 provided to an individual when obtaining medical cannabis: 228 (i) in the medical cannabis pharmacy; 229 (ii) at the medical cannabis pharmacy's drive-through pick up window; or 230 (iii) in a medical cannabis shipment. 231 (51) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in Section 232 4-41-102. 233 (52) "THC analog" means the same as that term is defined in Section 4-41-102. 234 (53) "Total composite tetrahydrocannabinol" means all detectable forms of
 - tetrahydrocannabinol.

236	(54) "Total tetrahydrocannabinol" or "total THC" means the same as that term is defined in
237	Section 4-41-102.
238	Section 2. Section 4-41a-103 is amended to read:
239	4-41a-103 . Inventory control system.
240	(1) Each cannabis production establishment and each medical cannabis pharmacy shall
241	maintain an inventory control system that meets the requirements of this section.
242	(2) A cannabis production establishment and a medical cannabis pharmacy shall ensure that
243	the inventory control system maintained by the establishment or pharmacy:
244	(a) tracks cannabis using a unique identifier, in real time, from the point that a cannabis
245	plant is eight inches tall and has a root ball until the cannabis is disposed of or sold,
246	in the form of unprocessed cannabis or a cannabis product, to an individual with a
247	medical cannabis card;
248	(b) maintains in real time a record of the amount of cannabis and cannabis products in
249	the possession of the establishment or pharmacy; and
250	[(c) includes a video recording system that:]
251	[(i) tracks all handling and processing of cannabis or a cannabis product in the
252	establishment or pharmacy;]
253	[(ii) is tamper proof; and]
254	[(iii) stores a video record for at least 45 days; and]
255	[(d)] (c) preserves compatibility with the state electronic verification system described in
256	Section 26B-4-202.
257	(3) A cannabis production establishment and a medical cannabis pharmacy shall allow the
258	following to access the cannabis production establishment's or the medical cannabis
259	pharmacy's inventory control system at any time:
260	(a) the department;
261	(b) the Department of Health and Human Services; and
262	(c) a financial institution that the Division of Finance validates, in accordance with
263	Subsection (6).
264	(4) The department may establish compatibility standards for an inventory control system
265	by rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
266	Act.
267	(5)(a) The department shall make rules in accordance with Title 63G, Chapter 3, Utah
268	Administrative Rulemaking Act, establishing requirements for aggregate or batch
269	records regarding the planting and propagation of cannabis before being tracked in an

270	inventory control system described in this section.
271	(b) The department shall ensure that the rules described in Subsection (5)(a) address
272	record-keeping for the amount of planted seed, number of cuttings taken, date and
273	time of cutting and planting, number of plants established, and number of plants
274	culled or dead.
275	(6)(a) The Division of Finance shall, in consultation with the state treasurer:
276	(i) in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
277	make rules to:
278	(A) establish a process for validating financial institutions for access to an
279	inventory control system in accordance with Subsections (3)(c) and (6)(b); and
280	(B) establish qualifications for the validation described in Subsection (6)(a)(i)(A);
281	(ii) review applications the Division of Finance receives in accordance with the
282	process established under Subsection (6)(a)(i);
283	(iii) validate a financial institution that meets the qualifications described in
284	Subsection (6)(a)(i); and
285	(iv) provide a list of validated financial institutions to the department and the
286	Department of Health and Human Services.
287	(b) A financial institution that the Division of Finance validates under Subsection (6)(a):
288	(i) may only access an inventory control system for the purpose of reconciling
289	transactions and other financial activity of cannabis production establishments,
290	medical cannabis pharmacies, and medical cannabis couriers that use financial
291	services that the financial institution provides;
292	(ii) may only access information related to financial transactions; and
293	(iii) may not access any identifying patient information.
294	Section 3. Section 4-41a-201 is amended to read:
295	4-41a-201 . Cannabis production establishment License.
296	(1) Except as provided in Subsection (14), a person may not operate a cannabis production
297	establishment without a license that the department issues under this chapter.
298	(2)(a)(i) Subject to Subsections (6), (7), (8), and (13) and to Section 4-41a-205, for a
299	licensing process that the department initiates after March 17, 2021, the
300	department, through the licensing board, shall issue licenses in accordance with
301	Section 4-41a-201.1.
302	(ii) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
303	the department shall make rules to specify a transparent and efficient process to:

304	(A) solicit applications for a license under this section;
305	(B) allow for comments and questions in the development of applications;
306	(C) timely and objectively evaluate applications;
307	(D) hold public hearings that the department deems appropriate; and
308	(E) select applicants to receive a license.
309	(iii) The department may not issue a license to operate a cannabis production
310	establishment to an applicant who is not eligible for a license under this section.
311	(b) An applicant is eligible for a license under this section if the applicant submits to the
312	licensing board:
313	(i) subject to Subsection (2)(c), a proposed name and address or, for a cannabis
314	cultivation facility, addresses of no more than two facility locations, located in a
315	zone described in Subsection 4-41a-406(2)(a) or (b), where the applicant will
316	operate the cannabis production establishment;
317	(ii) the name and address of any individual who has:
318	(A) for a publicly traded company, a financial or voting interest of 10% or greater
319	in the proposed cannabis production establishment;
320	(B) for a privately held company, a financial or voting interest in the proposed
321	cannabis production establishment; or
322	(C) the power to direct or cause the management or control of a proposed cannabis
323	production establishment;
324	(iii) an operating plan that:
325	(A) complies with Section 4-41a-204;
326	(B) includes operating procedures that comply with this chapter and any law the
327	municipality or county in which the person is located adopts that is consistent
328	with Section 4-41a-406; and
329	(C) the department or licensing board approves;
330	(iv) a statement that the applicant will obtain and maintain a liquid cash account with
331	a financial institution or a performance bond that a surety authorized to transact
332	surety business in the state issues in an amount of at least:
333	(A) \$100,000 for each cannabis cultivation facility for which the applicant applies;
334	or
335	(B) \$50,000 for each cannabis processing facility or independent cannabis testing
336	laboratory for which the applicant applies;
337	(v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the

338	department sets in accordance with Section 63J-1-504; and
339	(vi) a description of any investigation or adverse action taken by any licensing
340	jurisdiction, government agency, law enforcement agency, or court in any state for
341	any violation or detrimental conduct in relation to any of the applicant's
342	cannabis-related operations or businesses.
343	(c)(i) A person may not locate a cannabis production establishment:
344	(A) within 1,000 feet of a community location; or
345	(B) in or within 600 feet of a district that the relevant municipality or county has
346	zoned as primarily residential.
347	(ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured
348	from the nearest entrance to the cannabis production establishment by following
349	the shortest route of ordinary pedestrian travel to the property boundary of the
350	community location or residential area.
351	(iii) The licensing board may grant a waiver to reduce the proximity requirements in
352	Subsection (2)(c)(i) by up to 20% if the licensing board determines that it is not
353	reasonably feasible for the applicant to site the proposed cannabis production
354	establishment without the waiver.
355	(iv) An applicant for a license under this section shall provide evidence of
356	compliance with the proximity requirements described in Subsection (2)(c)(i).
357	(3) If the licensing board approves an application for a license under this section and
358	Section 4-41a-201.1:
359	(a) the applicant shall pay the [departmentan] department an initial license fee in an
360	amount that, subject to Subsection 4-41a-104(5), the department sets in accordance
361	with Section 63J-1-504; and
362	(b) the department shall notify the Department of Public Safety of the license approval
363	and the names of each individual described in Subsection (2)(b)(ii).
364	(4)(a) Except as provided in Subsection (4)(b), a cannabis production establishment
365	shall obtain a separate license for each type of cannabis production establishment and
366	each location of a cannabis production establishment.
367	(b) The licensing board may issue a cannabis cultivation facility license and a cannabis
368	processing facility license to a person to operate at the same physical location or at
369	separate physical locations.
370	(5) If the licensing board receives more than one application for a cannabis production
371	establishment within the same city or town, the licensing board shall consult with the

372	local land use authority before approving any of the applications pertaining to that city
373	or town.
374	(6) The licensing board may not issue a license to operate an independent cannabis testing
375	laboratory to a person who:
376	(a) holds a license or has an ownership interest in a medical cannabis pharmacy, a
377	cannabis processing facility, or a cannabis cultivation facility;
378	(b) has an owner, officer, director, or employee whose family member holds a license or
379	has an ownership interest in a medical cannabis pharmacy, a cannabis processing
380	facility, or a cannabis cultivation facility; or
381	(c) proposes to operate the independent cannabis testing laboratory at the same physical
382	location as a medical cannabis pharmacy, a cannabis processing facility, or a
383	cannabis cultivation facility.
384	(7) The licensing board may not issue a license to operate a cannabis production
385	establishment to an applicant if any individual described in Subsection (2)(b)(ii):
386	(a) has been convicted under state or federal law of:
387	(i) a felony in the preceding 10 years; or
388	(ii) after December 3, 2018, a misdemeanor for drug distribution;
389	(b) is younger than 21 years old; or
390	(c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
391	(8)(a) If an applicant for a cannabis production establishment license under this section
392	holds a license under Title 4, Chapter 41, Hemp and Cannabinoid Act, the licensing
393	board may not give preference to the applicant based on the applicant's status as a
394	holder of the license.
395	(b) If an applicant for a license to operate a cannabis cultivation facility under this
396	section holds a license to operate a medical cannabis pharmacy under this title, the
397	licensing board may give consideration to the applicant based on the applicant's
398	status as a holder of a medical cannabis pharmacy license if:
399	(i) the applicant demonstrates that a decrease in costs to patients is more likely to
400	result from the applicant's vertical integration than from a more competitive
401	marketplace; and
402	(ii) the licensing board finds multiple other factors, in addition to the existing license,
403	that support granting the new license.
404	(9) The licensing board may revoke a license under this part:
405	(a) if the cannabis production establishment does not begin cannabis production

406	operations within one year after the day on which the licensing board issues the
407	initial license;
408	(b) after the third of the same violation of this chapter in any of the licensee's licensed
409	cannabis production establishments or medical cannabis pharmacies;
410	(c) if any individual described in Subsection (2)(b) is convicted, while the license is
411	active, under state or federal law of:
412	(i) a felony; or
413	(ii) after December 3, 2018, a misdemeanor for drug distribution;
414	(d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
415	the time of application, or fails to supplement the information described in
416	Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the
417	submission of the application within 14 calendar days after the licensee receives
418	notice of the investigation or adverse action;
419	(e) if the cannabis production establishment demonstrates a willful or reckless disregard
420	for the requirements of this chapter or the rules the department makes in accordance
421	with this chapter;
422	(f) if, after a change of ownership described in Subsection (15)(b), the board determines
423	that the cannabis production establishment no longer meets the minimum standards
424	for licensure and operation of the cannabis production establishment described in this
425	chapter;
426	(g) for an independent cannabis testing laboratory, if the independent cannabis testing
427	laboratory fails to substantially meet the performance standards described in
428	Subsection (14)(b); or
429	(h) if, following an investigation conducted pursuant to Subsection 4-41a-201.1(11), the
430	board [identifies] finds that the licensee has participated in an anticompetitive
431	business [practices] practice.
432	(10)(a) A person who receives a cannabis production establishment license under this
433	chapter, if the municipality or county where the licensed cannabis production
434	establishment will be located requires a local land use permit, shall submit to the
435	licensing board a copy of the licensee's approved application for the land use permit
436	within 120 days after the day on which the licensing board issues the license.
437	(b) If a licensee fails to submit to the licensing board a copy of the licensee's approved
438	land use permit application in accordance with Subsection (10)(a), the licensing
439	board may revoke the licensee's license.

440	(11) The department shall deposit the proceeds of a fee that the department imposes under
441	this section into the Qualified Production Enterprise Fund.
442	(12) The department shall begin accepting applications under this part on or before January
443	1, 2020.
444	(13)(a) The department's authority, and consequently the licensing board's authority, to
445	issue a license under this section is plenary and is not subject to review.
446	(b) Notwithstanding Subsection (2)(a)(ii)(A), the decision of the department to award a
447	license to an applicant is not subject to:
448	(i) Title 63G, Chapter 6a, Part 16, Protests; or
449	(ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
450	(14)(a) Notwithstanding this section, the department:
451	(i) may operate or partner with a research university to operate an independent
452	cannabis testing laboratory;
453	(ii) if the department operates or partners with a research university to operate an
454	independent cannabis testing laboratory, may not cease operating or partnering
455	with a research university to operate the independent cannabis testing laboratory
456	unless:
457	(A) the department issues at least two licenses to independent cannabis testing
458	laboratories; and
459	(B) the department has ensured that the licensed independent cannabis testing
460	laboratories have sufficient capacity to provide the testing necessary to support
461	the state's medical cannabis market; and
462	(iii) after ceasing department or research university operations under Subsection
463	(14)(a)(ii) shall resume independent cannabis testing laboratory operations at any
464	time if:
465	(A) fewer than two licensed independent cannabis testing laboratories are
466	operating; or
467	(B) the licensed independent cannabis testing laboratories become, in the
468	department's determination, unable to fully meet the market demand for testing.
469	(b)(i) The department shall make rules, in accordance with Title 63G, Chapter 3,
470	Utah Administrative Rulemaking Act, to establish performance standards for the
471	operation of an independent cannabis testing laboratory, including deadlines for
472	testing completion.
473	(ii) A license that the department issues to an independent cannabis testing laboratory

474	is contingent upon substantial satisfaction of the performance standards described
475	in Subsection (14)(b)(i), as determined by the board.
476	(15)(a) A cannabis production establishment license is not transferrable or assignable.
477	(b) If the ownership of a cannabis production establishment changes by 50% or more:
478	(i) the cannabis production establishment shall submit a new application described in
479	Subsection (2)(b), subject to Subsection (2)(c);
480	(ii) within 30 days of the submission of the application, the board shall:
481	(A) conduct the application review described in Section 4-41a-201.1; and
482	(B) award a license to the cannabis production establishment for the remainder of
483	the term of the cannabis production establishment's license before the
484	ownership change if the cannabis production establishment meets the minimum
485	standards for licensure and operation of the cannabis production establishment
486	described in this chapter; and
487	(iii) if the board approves the license application, notwithstanding Subsection (3), the
488	cannabis production establishment shall pay a license fee that the department sets
489	in accordance with Section 63J-1-504 in an amount that covers the board's cost of
490	conducting the application review.
491	Section 4. Section 4-41a-201.1 is amended to read:
492	4-41a-201.1 . Cannabis Production Establishment and Pharmacy Licensing
493	Advisory Board Composition Duties.
494	(1) There is created within the department the Cannabis Production Establishment and
495	Pharmacy Licensing Advisory Board.
496	(2) The commissioner shall:
497	(a) appoint the members of the [board] licensing board;
498	(b) submit the name of each individual that the commissioner appoints under Subsection
499	(2)(a) to the governor for confirmation or rejection; and
500	(c) if the governor rejects an appointee that the commissioner submits under Subsection
501	(2)(b), appoint another individual in accordance with this Subsection (2).
502	(3)(a) Except as provided in Subsection [(3)(c)] (3)(b), the [board] licensing board shall
503	consist of the following eight members:
504	(i) the following seven voting members whom the commissioner appoints:
505	(A) one member of the public;
506	(B) one member with knowledge and experience in the pharmaceutical or
507	nutraceutical manufacturing industry;

500	
508	(C) one member representing law enforcement;(C) one member representing law enforcement;
509	(D) one member whom an organization representing medical cannabis patients
510	recommends;
511	(E) a chemist who has experience with cannabis and who is associated with a
512	research university;
513	(F) a pharmacist who is not associated with the medical cannabis industry; and
514	(G) an accountant; and
515	(ii) the commissioner or the commissioner's designee as a non-voting member, except
516	to cast a deciding vote in the event of a tie.
517	(b) The commissioner may appoint a ninth member to the [board] licensing board who
518	has a background in the cannabis cultivation and processing industry.
519	(c) The commissioner or the commissioner's designee shall serve as the chair of the [
520	board] licensing board.
521	(d) An individual is not eligible for appointment to be a member of the [board] licensing
522	board if the individual:
523	(i) has any commercial or ownership interest in a cannabis production establishment,
524	medical cannabis pharmacy, or medical cannabis courier;
525	(ii) has an owner, officer, director, or employee whose family member holds a license
526	or has an ownership interest in a cannabis production establishment, medical
527	cannabis pharmacy, or medical cannabis courier; or
528	(iii) is employed or contracted to lobby on behalf of any cannabis production
529	establishment, medical cannabis pharmacy, or medical cannabis courier.
530	(4)(a) Except as provided in Subsection (4)(b), a voting [board] licensing board member
531	shall serve a term of four years, beginning July 1 and ending June 30.
532	(b) Notwithstanding Subsection (4)(a), for the initial appointments to the [board]
533	licensing board, the commissioner shall stagger the length of the terms of [board]
534	licensing board members to ensure that the commissioner appoints two or three [board]
535	licensing board members every two years.
536	(c) As a [board] licensing board member's term expires:
537	(i) the [board] licensing board member is eligible for reappointment; and
538	(ii) the commissioner shall make an appointment, in accordance with Subsection (2),
539	for the new term before the end of the member's term.
540	(d) When a vacancy occurs on the [board] licensing board for any reason other than the
541	expiration of a [board] licensing board member's term, the commissioner shall appoint

542	a replacement to the vacant position, in accordance with Subsection (2), for the
543	unexpired term.
544	(e) In making appointments, the commissioner shall ensure that no two members of the [
545	board] licensing board are employed by or represent the same company or nonprofit
546	organization.
547	(f) The commissioner may remove a [board] licensing board member for cause, neglect
548	of duty, inefficiency, or malfeasance.
549	(5)(a)(i) Five members of the [board] licensing board constitute a quorum of the [
550	board] licensing board.
551	(ii) An action of the majority of the [board] licensing board members when a quorum
552	is present constitutes an action of the [board] licensing board.
553	(b) The department shall provide staff support to the [board] licensing board.
554	(c) A member of the [board] licensing board may not receive compensation or benefits
555	for the member's service, but may receive per diem and travel expenses in accordance
556	with:
557	(i) Section 63A-3-106;
558	(ii) Section 63A-3-107; and
559	(iii) rules made by the Division of Finance in accordance with Sections 63A-3-106
560	and 63A-3-107.
561	(6) The [board] licensing board shall:
562	(a) meet as called by the chair to review cannabis production establishment[-and],
563	medical cannabis pharmacy, and medical cannabis courier license applications;
564	(b) review each license application for compliance with:
565	(i) this chapter; and
566	(ii) department rules;
567	(c) conduct a public hearing to consider the license application;
568	(d) approve the department's license application forms and checklists; and
569	(e) make a determination on each license application.
570	(7) The [board] licensing board shall hold a public hearing to review a cannabis production
571	establishment's or medical cannabis pharmacy's license if the establishment:
572	(a) changes ownership by an interest of 20% or more;
573	(b) changes or adds a location;
574	(c) upgrades to a different licensing tier under department rule;
575	(d) changes extraction or formulation standard operating procedures;

576	(e) adds an industrial hemp processing or cultivation license to the same location as the
577	cannabis production establishment's processing facility; or
578	(f) as necessary based on the recommendation of the department.
579	(8) In a public hearing held under Subsection (7), the [board] licensing board may consider
580	the following in determining whether to approve a request to change pharmacy locations:
581	(a) medical cannabis availability, quality, and variety;
582	(b) whether geographic dispersal among licensees is sufficient to reasonably maximize
583	access to the largest number of medical cannabis cardholders;
584	(c) the extent to which the pharmacy can increase efficiency and reduce the cost to
585	patients of medical cannabis; and
586	(d) the factors listed in Subsection 4-41a-1004(7).
587	(9) In a public hearing held pursuant to Subsection (7), the [board] licensing board may not
588	approve a request to change a medical cannabis pharmacy location outside of the
589	pharmacy's current region established under Subsection 4-41a-1005(1)(c)(ii)(A).
590	(10)(a) The [board] licensing board shall meet [annually in December] as necessary to
591	consider cannabis production establishment[-and], medical cannabis pharmacy, and
592	medical cannabis courier license renewal applications.
593	(b) During the meeting described in Subsection (10)(a):
594	(i) a representative from each applicant for renewal shall:
595	(A) attend in person or electronically; or
596	(B) submit information before the meeting, as the [board] licensing board may
597	require, for the [board] licensing board's consideration;
598	(ii) the [board] licensing board shall consider, for each cannabis cultivation facility
599	seeking renewal, information including:
600	(A) the amount of biomass the licensee produced during the current calendar year;
601	(B) the amount of biomass the licensee projects to produce during the following
602	year;
603	(C) the amount of hemp waste the licensee currently holds;
604	(D) the current square footage or acres of growing area the licensee uses; and
605	(E) the square footage or acres of growing area the licensee projects to use in the
606	following year;
607	(iii) the [board] licensing board shall consider, for each cannabis processing facility
608	seeking renewal, information including:
609	(A) methods and procedures for extraction;

610	(B) standard operating procedures; and
611	(C) a complete listing of the medical dosage forms that the licensee produces; and
612	(iv) the [board] licensing board shall consider, for each cannabis pharmacy seeking
613	renewal, information including:
614	(A) product availability, quality, and variety;
615	(B) the pharmacy's operating procedures and practices; and
616	(C) the factors listed in Subsection 4-41a-1003(1).
617	(c) Following consideration of the information provided under Subsection (10)(b), the [
618	board] licensing board may elect to approve, deny, or issue conditional approval of a
619	cannabis production establishment or pharmacy license renewal application.
620	(d) The information a licensee or license applicant provides to the [board] licensing board
621	for a license determination constitutes a protected record under Subsection
622	63G-2-305(1) or (2) if the applicant or licensee provides the [board] licensing board
623	with the information regarding business confidentiality required in Section
623a	63G-2-309.
624	(11)(a) In cooperation with the attorney general, the [board] licensing board may
625	investigate information received by the department indicating that a licensee is
626	potentially engaging in anticompetitive business practices.
627	(b) In investigating potential anticompetitive business practices under this section, the
628	attorney general may issue civil investigative demands as set forth in Section
629	<u>76-10-3107.</u>
630	(12) The department shall:
631	(a) provide staff support for the licensing board;
632	(b) assist the licensing board in conducting meetings; and
633	(c) review all submitted applications for completion and accuracy.
634	Section 5. Section 4-41a-401 is amended to read:
635	4-41a-401 . Cannabis production establishment General operating
636	requirements.
637	(1)(a) A cannabis production establishment shall operate in accordance with the
638	operating plan described in Sections 4-41a-201 and 4-41a-204.
639	(b) A cannabis production establishment shall notify the department before a change in
640	the cannabis production establishment's operating plan.
641	(c)(i) If a cannabis production establishment changes the cannabis production
642	establishment's operating plan, the establishment shall ensure that the new

643	operating plan complies with this chapter.
644	(ii) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
645	Utah Administrative Rulemaking Act, a process to:
646	(A) review a change notification described in Subsection (1)(b);
647	(B) identify for the cannabis production establishment each point of
648	noncompliance between the new operating plan and this chapter;
649	(C) provide an opportunity for the cannabis production establishment to address
650	each identified point of noncompliance; and
651	(D) suspend or revoke a license if the cannabis production establishment fails to
652	cure the noncompliance.
653	(2) A cannabis production establishment shall operate:
654	(a) except as provided in Subsection (5), in a facility that is accessible only by an
655	individual with a valid cannabis production establishment agent registration card
656	issued under Section 4-41a-301; and
657	(b) at the physical address provided to the department under Section 4-41a-201.
658	(3) A cannabis production establishment may not employ an individual who is younger than
659	21 years old.
660	(4) A cannabis production establishment may not employ an individual who has been
661	convicted, under state or federal law, of:
662	(a) a felony in the preceding 10 years; or
663	(b) after December 3, 2018, a misdemeanor for drug distribution.
664	(5) A cannabis production establishment may authorize an individual who is at least 18
665	years old and is not a cannabis production establishment agent to access the cannabis
666	production establishment if the cannabis production establishment:
667	(a) tracks and monitors the individual at all times while the individual is at the cannabis
668	production establishment; and
669	(b) maintains a record of the individual's access, including arrival and departure.
670	(6) A cannabis production establishment shall operate in a facility that has:
671	(a) a single, secure public entrance;
672	(b) a security system with a backup power source that:
673	(i) detects and records entry into the cannabis production establishment; and
674	(ii) provides notice of an unauthorized entry to law enforcement when the cannabis
675	production establishment is closed; and
676	(c) a lock or equivalent restrictive security feature on any area where the cannabis

677	production establishment stores cannabis or a cannabis product.
678	(7)(a) A cannabis production establishment shall maintain a video surveillance system
679	that:
680	(i) tracks all handling and processing of cannabis or a cannabis product in the
681	establishment;
682	(ii) is tamper proof; and
683	(iii) stores a video record for at least 45 days.
684	(b) A cannabis production establishment shall provide the department access to the
685	video surveillance system upon request.
686	Section 6. Section 4-41a-801 is amended to read:
687	4-41a-801 . Enforcement Fine Citation.
688	(1) If a person that is a cannabis production establishment or a cannabis production
689	establishment agent violates this chapter, the department may:
690	(a) revoke the person's license or cannabis production establishment agent registration
691	card;
692	(b) decline to renew the person's license or cannabis production establishment agent
693	registration card; or
694	(c) assess the person an administrative penalty that the department establishes by rule in
695	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
696	(2) The department shall deposit an administrative penalty imposed under this section into
697	the General Fund.
698	(3)(a) The department may take an action described in Subsection (3)(b) if the
699	department concludes, upon investigation, that, for a person that is a cannabis
700	production establishment or a cannabis production establishment agent:
701	(i) the person has violated the provisions of this chapter, a rule made under this
702	chapter, or an order issued under this chapter; or
703	(ii) the person produced cannabis or a cannabis product batch that contains a
704	substance, other than cannabis, that poses a significant threat to human health.
705	(b) If the department makes the determination about a person described in Subsection
706	(3)(a), the department shall:
707	(i) issue the person a written administrative citation;
708	(ii) attempt to negotiate a stipulated settlement;
709	(iii) seize, embargo, or destroy the cannabis or cannabis product batch;
710	(iv) order the person to cease and desist from the action that creates a violation; and

711	(v) direct the person to appear before an adjudicative proceeding conducted under
712	Title 63G, Chapter 4, Administrative Procedures Act.
713	(4) The department may, for a person subject to an uncontested citation, a stipulated
714	settlement, or a finding of a violation in an adjudicative proceeding under this section,
715	for a fine amount not already specified in law, assess the person, who is not an
716	individual, a fine of up to \$5,000 per violation, in accordance with a fine schedule that
717	the department establishes by rule in accordance with Title 63G, Chapter 3, Utah
718	Administrative Rulemaking Act.
719	(5) The department may not revoke a cannabis production establishment's license without
720	first directing the cannabis production establishment to appear before an adjudicative
721	proceeding conducted under Title 63G, Chapter 4, Administrative Procedures Act.
722	(6) If within 20 calendar days after the day on which a department serves a citation for a
723	violation of this chapter, the person that is the subject of the citation fails to request a
724	hearing to contest the citation, the citation becomes the department's final order.
725	(7) The department may, for a person who fails to comply with a citation under this section:
726	(a) refuse to issue or renew the person's license or cannabis production establishment
727	agent registration card; or
728	(b) suspend, revoke, or place on probation the person's license or cannabis production
729	establishment registration card.
730	(8)(a) Except where a criminal penalty is expressly provided for a specific violation of
731	this chapter, or where civil and criminal penalties are provided for violations of
732	Section 76-10-31, if an individual:
733	(i) violates a provision of this chapter, the individual is:
734	(A) guilty of an infraction; and
735	(B) subject to a \$100 fine; or
736	(ii) intentionally or knowingly violates a provision of this chapter or violates this
737	chapter three or more times, the individual is:
738	(A) guilty of a class B misdemeanor; and
739	(B) subject to a \$1,000 fine.
740	(b) An individual who is guilty of a violation described in Subsection (8)(a) is not guilty
741	of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the
742	conduct underlying the violation described in Subsection (8)(a).
743	(9) Nothing in this section prohibits:
744	(a) the department from referring potential criminal activity to law enforcement[-]; or

745	(b) the attorney general from investigating or prosecuting individuals or businesses for
746	violations of Title 76, Chapter 10, Part 31, Utah Antitrust Act.
747	Section 7. Section 4-41a-802 is amended to read:
748	4-41a-802 . Report.
749	(1) At or before the November interim meeting each year, the department shall report to the
750	Health and Human Services Interim Committee on:
751	(a) the number of applications and renewal applications that the department receives
752	under this chapter;
753	(b) the number of each type of [cannabis production facility] license that the department [
754	licenses] issues in each county;
755	(c) the amount of cannabis that licensees grow;
756	(d) the amount of cannabis that licensees manufacture into cannabis products;
757	(e) the number of licenses the department revokes under this chapter;
758	(f) the department's operation of an independent cannabis testing laboratory under
759	Section 4-41a-201, including:
760	(i) the cannabis and cannabis products the department tested; and
761	(ii) the results of the tests the department performed;
762	(g) the expenses incurred and revenues generated under this chapter; [and]
763	(h) the total quantity of medical cannabis shipments;
764	(i) the number of overall purchases of medical cannabis from each medical cannabis
765	pharmacy; and
766	[(h)] (j) an analysis of product availability in medical cannabis pharmacies in
767	consultation with the Department of Health and Human Services.
768	(2) The department may not include personally identifying information in the report
769	described in this section.
770	(3) The department shall report to the working group described in Section 36-12-8.2 as
771	requested by the working group.
772	Section 8. Section 4-41a-1001 is amended to read:
773	4-41a-1001 . Medical cannabis pharmacy License Eligibility.
774	(1) A person may not:
775	(a) operate as a medical cannabis pharmacy without a license that the department issues
776	under this part;
777	(b) obtain a medical cannabis pharmacy license if obtaining the license would cause the
778	person to exceed the pharmacy ownership limit;

779	(c) obtain a partial ownership share of a medical cannabis pharmacy if obtaining the
780	partial ownership share would cause the person to exceed the pharmacy ownership
781	limit; or
782	(d) enter into any contract or agreement that allows the person to directly or indirectly
783	control the operations of a medical cannabis pharmacy if the person's control of the
784	medical cannabis pharmacy would cause the person to effectively exceed the
785	pharmacy ownership limit.
786	(2)(a)(i) Subject to Subsections (4) and (5) and to Section 4-41a-1005, the [
787	department shall issue a license to operate a medical cannabis pharmacy through
788	the licensing board created under Section 4-41a-201.1] licensing board shall issue
789	a license to operate a medical cannabis pharmacy.
790	(ii) The [department] licensing board may not issue a license to operate a medical
791	cannabis pharmacy to an applicant who is not eligible for a license under this
792	section.
793	(b) An applicant is eligible for a license under this section if the applicant submits to the [
794	department] licensing board:
795	(i) subject to Subsection (2)(c), a proposed name and address where the applicant will
796	operate the medical cannabis pharmacy;
797	(ii) the name and address of an individual who:
798	(A) for a publicly traded company, has a financial or voting interest of 10% or
799	greater in the proposed medical cannabis pharmacy;
800	(B) for a privately held company, a financial or voting interest in the proposed
801	medical cannabis pharmacy; or
802	(C) has the power to direct or cause the management or control of a proposed
803	medical cannabis pharmacy;
804	(iii) for each application that the applicant submits to the department, a statement
805	from the applicant that the applicant will obtain and maintain:
806	(A) a performance bond in the amount of \$100,000 issued by a surety authorized
807	to transact surety business in the state; or
808	(B) a liquid cash account in the amount of \$100,000 with a financial institution;
809	(iv) an operating plan that:
810	(A) complies with Section 4-41a-1004;
811	(B) includes operating procedures to comply with the operating requirements for a
812	medical cannabis pharmacy described in this part and with a relevant municipal

813	or county law that is consistent with Section 4-41a-1106; and
814	(C) the department approves;
815	(v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the
816	department sets in accordance with Section 63J-1-504; and
817	(vi) a description of any investigation or adverse action taken by any licensing
818	jurisdiction, government agency, law enforcement agency, or court in any state for
819	any violation or detrimental conduct in relation to any of the applicant's
820	cannabis-related operations or businesses.
821	(c)(i) A person may not locate a medical cannabis pharmacy:
822	(A) within 200 feet of a community location; or
823	(B) in or within 600 feet of a district that the relevant municipality or county has
824	zoned as primarily residential.
825	(ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured
826	from the nearest entrance to the medical cannabis pharmacy establishment by
827	following the shortest route of ordinary pedestrian travel to the property boundary
828	of the community location or residential area.
829	(iii) The [department] licensing board may grant a waiver to reduce the proximity
830	requirements in Subsection (2)(c)(i) by up to 20% if the department determines
831	that it is not reasonably feasible for the applicant to cite the proposed medical
832	cannabis pharmacy without the waiver.
833	(iv) An applicant for a license under this section shall provide evidence of
834	compliance with the proximity requirements described in Subsection (2)(c)(i).
835	(d) The [department] licensing board may not issue a license to an eligible applicant that
836	the department has selected to receive a license until the selected eligible applicant
837	complies with the bond or liquid cash requirement described in Subsection (2)(b)(iii).
838	(e) If the [department] licensing board receives more than one application for a medical
839	cannabis pharmacy within the same city or town, the department shall consult with
840	the local land use authority before approving any of the applications pertaining to that
841	city or town.
842	(f) In considering the issuance of a medical cannabis pharmacy license under this
843	section, the [department] licensing board may consider the extent to which the
844	pharmacy can increase efficiency and reduce cost to patients of medical cannabis.
845	(3) If the [department] licensing board selects an applicant for a medical cannabis pharmacy
846	license under this section, the department shall:

847	(a) charge the applicant an initial license fee in an amount that, subject to Subsection
848	4-41a-104(5), the department sets in accordance with Section 63J-1-504;
849	(b) notify the Department of Public Safety of the license approval and the names of each
850	individual described in Subsection (2)(b)(ii); and
851	(c) charge the licensee a fee in an amount that, subject to Subsection 4-41a-104(5), the
852	department sets in accordance with Section 63J-1-504, for any change in location,
853	ownership, or company structure.
854	(4) The [department] licensing board may not issue a license to operate a medical cannabis
855	pharmacy to an applicant if an individual described in Subsection (2)(b)(ii):
856	(a) has been convicted under state or federal law of:
857	(i) a felony in the preceding 10 years; or
858	(ii) after December 3, 2018, a misdemeanor for drug distribution;
859	(b) is younger than 21 years old; or
860	(c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
861	(5)(a) If an applicant for a medical cannabis pharmacy license under this section holds
862	another license under this chapter, the [department] licensing board may not give
863	preference to the applicant based on the applicant's status as a holder of the license.
864	(b) If an applicant for a medical cannabis pharmacy license under this section holds a
865	license to operate a cannabis cultivation facility under this section, the [department]
866	licensing board may give consideration to the applicant's status as a holder of the
867	license if:
868	(i) the applicant demonstrates that a decrease in costs to patients is more likely to
869	result from the applicant's vertical integration than from a more competitive
870	marketplace; and
871	(ii) the department finds multiple other factors, in addition to the existing license, that
872	support granting the new license.
873	(6) The [licensing board] licensing board may revoke a license under this part:
874	(a) if the medical cannabis pharmacy does not begin operations within one year after the
875	day on which the department issues an announcement of the department's intent to
876	award a license to the medical cannabis pharmacy;
877	(b) after the third <u>of</u> the same violation of this chapter in any of the licensee's licensed
878	cannabis production establishments or medical cannabis pharmacies;
879	(c) if an individual described in Subsection (2)(b)(ii) is convicted, while the license is
880	active, under state or federal law of:

881	(i) a felony; or
882	(ii) after December 3, 2018, a misdemeanor for drug distribution;
883	(d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
884	the time of application, or fails to supplement the information described in
885	Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the
886	submission of the application within 14 calendar days after the licensee receives
887	notice of the investigation or adverse action;
888	(e) if the medical cannabis pharmacy demonstrates a willful or reckless disregard for the
889	requirements of this chapter or the rules the department makes in accordance with
890	this chapter;
891	(f) if, after a change of ownership described in Subsection $[(11)(c)]$ (10)(c), the
892	department determines that the medical cannabis pharmacy no longer meets the
893	minimum standards for licensure and operation of the medical cannabis pharmacy
894	described in this chapter; or
895	(g) if through an investigation conducted under Subsection 4-41a-201.1(11) and in
896	accordance with Title 63G, Chapter 4, Administrative Procedures Act, the [board]
897	licensing board finds that the licensee has participated in anticompetitive business
898	practices.
899	(7)(a) A person who receives a medical cannabis pharmacy license under this chapter, if
900	the municipality or county where the licensed medical cannabis pharmacy will be
901	located requires a local land use permit, shall submit to the department a copy of the
902	licensee's approved application for the land use permit within 120 days after the day
903	on which the department issues the license.
904	(b) If a licensee fails to submit to the department a copy the licensee's approved land use
905	permit application in accordance with Subsection (7)(a), the department may revoke
906	the licensee's license.
907	(8) The department shall deposit the proceeds of a fee imposed by this section into the
908	Qualified Production Enterprise Fund.
909	[(9) The department shall begin accepting applications under this part on or before March
910	1, 2020.]
911	[(10)] (9)(a) The [department's] licensing board's authority to issue a license under this
912	section is plenary and is not subject to review.
913	(b) Notwithstanding Subsection (2), the decision of the department to award a license to
914	an applicant is not subject to:

915	(i) Title 63G, Chapter 6a, Part 16, Protests; or
916	(ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
917	[(11)] (10)(a) A medical cannabis pharmacy license is not transferrable or assignable.
918	(b) A medical cannabis pharmacy shall report in writing to the department no later than [
919	10] <u>45</u> business days before the date of any change of ownership of the medical
920	cannabis pharmacy.
921	(c) If the ownership of a medical cannabis pharmacy changes by 50% or more:
922	(i) concurrent with the report described in Subsection $[(11)(b)]$ (10)(b), the medical
923	cannabis pharmacy shall submit a new application described in Subsection (2)(b),
924	subject to Subsection (2)(c);
925	(ii) within 30 days of the submission of the application, the [department] licensing
926	board shall:
927	(A) conduct an application review; and
928	(B) award a license to the medical cannabis pharmacy for the remainder of the
929	term of the medical cannabis pharmacy's license before the ownership change
930	if the medical cannabis pharmacy meets the minimum standards for licensure
931	and operation of the medical cannabis pharmacy described in this chapter; and
932	(iii) if the department approves the license application, notwithstanding Subsection
933	(3), the medical cannabis pharmacy shall pay a license fee that the department sets
934	in accordance with Section 63J-1-504 in an amount that covers the department's
935	cost of conducting the application review.
936	Section 9. Section 4-41a-1101 is amended to read:
937	4-41a-1101 . Operating requirements General.
938	(1)(a) A medical cannabis pharmacy shall operate:
939	(i) at the physical address provided to the department under Section 4-41a-1001; and
940	(ii) in accordance with the operating plan provided to the department under Section
941	4-41a-1001 and, if applicable, Section 4-41a-1004.
942	(b) A medical cannabis pharmacy shall notify the department before a change in the
943	medical cannabis pharmacy's physical address or operating plan.
944	(2) An individual may not enter a medical cannabis pharmacy unless the individual:
945	(a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and
946	(b) except as provided in Subsection (4):
947	(i) possesses a valid:
948	(A) medical cannabis pharmacy agent registration card;

949	(B) pharmacy medical provider registration card; or
950	(C) medical cannabis card;
951	(ii) is an employee of the department performing an inspection under Section
952	4-41a-1103; or
953	(iii) is another individual as the department provides.
954	(3) A medical cannabis pharmacy may not employ an individual who is younger than 21
955	years old.
956	(4) Notwithstanding Subsection (2)(a), a medical cannabis pharmacy may authorize an
957	individual who is not a medical cannabis pharmacy agent or pharmacy medical provider
958	to access the medical cannabis pharmacy if the medical cannabis pharmacy tracks and
959	monitors the individual at all times while the individual is at the medical cannabis
960	pharmacy and maintains a record of the individual's access.
961	(5) A medical cannabis pharmacy shall operate in a facility that has:
962	(a) a single, secure public entrance;
963	(b) a security system with a backup power source that:
964	(i) detects and records entry into the medical cannabis pharmacy; and
965	(ii) provides notice of an unauthorized entry to law enforcement when the medical
966	cannabis pharmacy is closed; and
967	(c) a lock on each area where the medical cannabis pharmacy stores cannabis or a
968	cannabis product.
969	(6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the medical
970	cannabis pharmacy, the limit on the purchase of cannabis described in Subsection
971	4-41a-1102(2).
972	(7) Except for an emergency situation described in Subsection [26B-4-213(3)(c)]
973	<u>26B-4-213(3)(b)</u> , a medical cannabis pharmacy may not allow any individual to
974	consume cannabis on the property or premises of the medical cannabis pharmacy.
975	(8) A medical cannabis pharmacy may not sell cannabis or a cannabis product without first
976	indicating on the cannabis or cannabis product label the name of the medical cannabis
977	pharmacy.
978	(9)(a) Each medical cannabis pharmacy shall retain in the pharmacy's records the
979	following information regarding each recommendation underlying a transaction:
980	(i) the recommending medical provider's name, address, and telephone number;
981	(ii) the patient's name and address;
982	(iii) the date of issuance;

983	(iv) directions of use and dosing guidelines or an indication that the recommending
984	medical provider did not recommend specific directions of use or dosing
985	guidelines; and
986	(v) if the patient did not complete the transaction, the name of the medical cannabis
987	cardholder who completed the transaction.
988	(b)(i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
989	not sell medical cannabis unless the medical cannabis has a label securely affixed
990	to the container indicating the following minimum information:
991	(A) the name, address, and telephone number of the medical cannabis pharmacy;
992	(B) the unique identification number that the medical cannabis pharmacy assigns;
993	(C) the date of the sale;
994	(D) the name of the patient;
995	(E) the name of the recommending medical provider who recommended the
996	medical cannabis treatment;
997	(F) directions for use and cautionary statements, if any;
998	(G) the amount dispensed and the cannabinoid content;
999	(H) the suggested use date;
1000	(I) for unprocessed cannabis flower, the legal use termination date; and
1001	(J) any other requirements that the department determines, in consultation with the
1002	Division of Professional Licensing and the Board of Pharmacy.
1003	(ii) A medical cannabis pharmacy is exempt from the requirement to provide the
1004	following information under Subsection (9)(b)(i) if the information is already
1005	provided on the product label that a cannabis production establishment affixes:
1006	(A) a unique identification number;
1007	(B) directions for use and cautionary statements;
1008	(C) amount and cannabinoid content; and
1009	(D) a suggested use date.
1010	(iii) If the size of a medical cannabis container does not allow sufficient space to
1011	include the labeling requirements described in Subsection (9)(b)(i), the medical
1012	cannabis pharmacy may provide the following information described in
1013	Subsection (9)(b)(i) on a supplemental label attached to the container or an
1014	informational enclosure that accompanies the container:
1015	(A) the cannabinoid content;
1016	(B) the suggested use date; and

1017	(C) any other requirements that the department determines.
1018	(iv) A medical cannabis pharmacy may sell medical cannabis to another medical
1019	cannabis pharmacy without a label described in Subsection (9)(b)(i).
1020	(10) A pharmacy medical provider or medical cannabis pharmacy agent shall:
1021	(a) upon receipt of an order from a limited medical provider in accordance with
1022	Subsections 26B-4-204(1)(b) through (d):
1023	(i) for a written order or an electronic order under circumstances that the department
1024	determines, contact the limited medical provider or the limited medical provider's
1025	office to verify the validity of the recommendation; and
1026	(ii) for an order that the pharmacy medical provider or medical cannabis pharmacy
1027	agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject
1028	to verification under Subsection (10)(a)(i), enter the limited medical provider's
1029	recommendation or renewal, including any associated directions of use, dosing
1030	guidelines, or caregiver indication, in the state electronic verification system;
1031	(b) in processing an order for a holder of a conditional medical cannabis card described
1032	in Subsection 26B-4-213(1)(b) that appears irregular or suspicious in the judgment of
1033	the pharmacy medical provider or medical cannabis pharmacy agent, contact the
1034	recommending medical provider or the recommending medical provider's office to
1035	verify the validity of the recommendation before processing the cardholder's order;
1036	(c) unless the medical cannabis cardholder has had a consultation under Subsection
1037	26B-4-231(5), verbally offer to a medical cannabis cardholder at the time of a
1038	purchase of cannabis, a cannabis product, or a medical cannabis device, personal
1039	counseling with the pharmacy medical provider; and
1040	(d) provide a telephone number or website by which the cardholder may contact a
1041	pharmacy medical provider for counseling.
1042	(11)(a) A medical cannabis pharmacy may create a medical cannabis disposal program
1043	that allows an individual to deposit unused or excess medical cannabis or cannabis
1044	residue from a medical cannabis device in a locked box or other secure receptacle
1045	within the medical cannabis pharmacy.
1046	(b) A medical cannabis pharmacy with a disposal program described in Subsection
1047	(11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy
1048	medical provider can access deposited medical cannabis.
1049	(c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis by:
1050	(i) rendering the deposited medical cannabis unusable and unrecognizable before

1051	transporting deposited medical cannabis from the medical cannabis pharmacy; and
1052	(ii) disposing of the deposited medical cannabis in accordance with:
1053	(A) federal and state law, rules, and regulations related to hazardous waste;
1054	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
1055	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
1056	(D) other regulations that the department makes in accordance with Title 63G,
1057	Chapter 3, Utah Administrative Rulemaking Act.
1058	(12) A medical cannabis pharmacy:
1059	(a) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy
1060	Practice Act, as a pharmacy medical provider;
1061	(b) may employ a physician who has the authority to write a prescription and is licensed
1062	under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
1063	Osteopathic Medical Practice Act, as a pharmacy medical provider;
1064	(c) shall ensure that a pharmacy medical provider described in Subsection (12)(a) works
1065	onsite during all business hours;
1066	(d) shall designate one pharmacy medical provider described in Subsection (12)(a) as the
1067	pharmacist-in-charge to oversee the operation of and generally supervise the medical
1068	cannabis pharmacy; [and]
1069	(e) shall allow the pharmacist-in-charge to determine which cannabis and cannabis
1070	products the medical cannabis pharmacy maintains in the medical cannabis
1071	pharmacy's inventory[-] :
1072	(f) shall maintain a video surveillance system that:
1073	(i) tracks all handling of medical cannabis in the pharmacy;
1074	(ii) is tamper proof; and
1075	(iii) stores a video record for at least 45 days; and
1076	(g) shall provide the department access to the video surveillance system upon request.
1077	(13) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
1078	Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products
1079	by a medical cannabis pharmacy.
1080	Section 10. Section 4-41a-1102 is amended to read:
1081	4-41a-1102 . Dispensing Amount a medical cannabis pharmacy may dispense
1082	Reporting Form of cannabis or cannabis product.
1083	(1)(a) A medical cannabis pharmacy may not sell a product other than:
1084	[(i) cannabis in a medicinal dosage form that the medical cannabis pharmacy

1085	acquired from another medical cannabis pharmacy or a cannabis processing
1086	facility that is licensed under Section 4-41a-201;]
1087	[(ii)] (i) [a cannabis product in a medicinal dosage form] medical cannabis that the
1088	medical cannabis pharmacy acquired from another medical cannabis pharmacy or
1089	a cannabis processing facility that is licensed under Section 4-41a-201;
1090	[(iii)] (ii) a medical cannabis device; or
1091	[(iv)] (iii) educational material related to the medical use of cannabis.
1092	(b) A medical cannabis pharmacy may only sell an item listed in Subsection (1)(a) to an
1093	individual with:
1094	(i)(A) a medical cannabis card; or
1095	(B) a Department of Health and Human Services registration described in
1096	Subsection 26B-4-213(10); and
1097	(ii) a corresponding government issued photo identification.
1098	(c) Notwithstanding Subsection (1)(a), a medical cannabis pharmacy may not sell a
1099	cannabis-based drug that the United States Food and Drug Administration has
1100	approved.
1101	(d) Notwithstanding Subsection (1)(b), a medical cannabis pharmacy may not sell a
1102	medical cannabis device or medical cannabis to an individual described in Subsection
1103	26B-4-213(2)(a)(i)(B) or to a minor described in Subsection 26B-4-213(2)(c) unless
1104	the individual or minor has the approval of the Compassionate Use Board in
1105	accordance with Subsection 26B-1-421(5).
1106	(2) A medical cannabis pharmacy:
1107	(a) may dispense to a medical cannabis cardholder, in any one 28-day period, up to the
1108	legal dosage limit of:
1109	(i) unprocessed cannabis that:
1110	(A) is in a medicinal dosage form; and
1111	(B) carries a label clearly displaying the amount of tetrahydrocannabinol and
1112	cannabidiol in the cannabis; and
1113	(ii) a cannabis product that is in a medicinal dosage form; and
1114	(b) may not dispense:
1115	(i) except for a medical cannabis cardholder approved under Subsection 26B-4-245(2),
1116	more medical cannabis than described in Subsection (2)(a); or
1117	(ii) any medical cannabis to an individual whose recommending medical provider did
1118	not recommend directions of use and dosing guidelines, until the individual

1119	consults with the pharmacy medical provider in accordance with Subsection
1120	26B-4-231(5).
1121	(3)(a) A medical cannabis pharmacy shall:
1122	(i)(A) access the state electronic verification system before dispensing [eannabis
1123	or a cannabis product] medical cannabis to a medical cannabis cardholder in
1124	order to determine if the cardholder or, where applicable, the associated patient
1125	has met the maximum amount of medical cannabis described in Subsection (2);
1126	and
1127	(B) if the verification in Subsection $(3)(a)(i)(A)$ indicates that the individual has
1128	met the maximum amount described in Subsection (2), decline the sale, and
1129	notify the recommending medical provider who made the underlying
1130	recommendation;
1131	(ii) submit a record to the state electronic verification system each time the medical
1132	cannabis pharmacy dispenses medical cannabis to a medical cannabis cardholder;
1133	(iii) ensure that the pharmacy medical provider who is a licensed pharmacist reviews
1134	each medical cannabis transaction before dispensing the medical cannabis to the
1135	cardholder in accordance with pharmacy practice standards;
1136	(iv) package any medical cannabis[that is] in a container that:
1137	(A) complies with Subsection 4-41a-602(1)(b) or, if applicable, provisions related
1138	to a container for unprocessed cannabis flower in the definition of "medicinal
1139	dosage form" in Section 26B-4-201; and
1140	(B) is tamper-resistant and tamper-evident; [and]
1141	[(C) provides an opaque bag or box for the medical cannabis cardholder's use in
1142	transporting the container in public;]
1143	(v) for a product that is a cube that is designed for ingestion through chewing or
1144	holding in the mouth for slow dissolution, include a separate, off-label warning
1145	about the risks of over-consumption; and
1146	(vi) beginning January 1, 2024, for [a cannabis product] medical cannabis that is
1147	cannabis flower, vaporizer cartridges, or concentrate, provide the product's terpene
1148	profiles collected under Subsection 4-41a-701(4) at or before the point of sale.
1149	(b) A medical cannabis cardholder transporting or possessing the container described in
1150	Subsection (3)(a)(iv) in public shall keep the container within the opaque bag or box
1151	that the medical cannabis pharmacist provides.
1152	(c) A medical cannabis pharmacy shall provide an opaque bag or box for the medical

1153	cannabis cardholder to use in transporting the medical cannabis in public if the
1154	medical cannabis cardholder does not provide an opaque bag or box.
1155	(4)(a) Except as provided in Subsection (4)(b), a medical cannabis pharmacy may not
1156	sell medical cannabis in the form of a cigarette or a medical cannabis device that is
1157	intentionally designed or constructed to resemble a cigarette.
1158	(b) A medical cannabis pharmacy may sell a medical cannabis device that warms
1159	cannabis material into a vapor without the use of a flame and that delivers cannabis to
1160	an individual's respiratory system.
1161	(5)(a) A medical cannabis pharmacy may not give, at no cost, a product that the medical
1162	cannabis pharmacy is allowed to sell under Subsection $(1)(a)(i)[,] \underline{or}(ii)[, or(iii)]$.
1163	(b) A medical cannabis pharmacy may give, at no cost, educational material related to
1164	the medical use of cannabis.
1165	(6) A medical cannabis pharmacy may purchase and store medical cannabis devices
1166	regardless of whether the seller has a cannabis-related license under this chapter or Title
1167	26B, Utah Health and Human Services Code.
1168	Section 11. Section 4-41a-1106 is amended to read:
1169	4-41a-1106 . Medical cannabis pharmacy agent Registration.
1170	(1) An individual may not serve as a medical cannabis pharmacy agent of a medical
1171	cannabis pharmacy unless the department registers the individual as a medical cannabis
1172	pharmacy agent.
1173	(2) A recommending medical provider may not act as a medical cannabis pharmacy agent,
1174	have a financial or voting interest of 2% or greater in a medical cannabis pharmacy, or
1175	have the power to direct or cause the management or control of a medical cannabis
1176	pharmacy.
1177	(3)(a) The department shall, within 15 days after the day on which the department
1178	receives a complete application from a medical cannabis pharmacy on behalf of a
1179	prospective medical cannabis pharmacy agent, register and issue a medical cannabis
1180	pharmacy agent registration card to the prospective agent if the medical cannabis
1181	pharmacy:
1182	(i) provides to the department:
1183	(A) the prospective agent's name and address;
1184	(B) the name and location of the licensed medical cannabis pharmacy where the
1185	prospective agent seeks to act as the medical cannabis pharmacy agent; and
1186	(C) the submission required under Subsection (3)(b); and

1187	(ii) pays a fee to the department in an amount that, subject to Subsection 4-41a-104
1188	(5), the department sets in accordance with Section 63J-1-504.
1189	(b) Each prospective agent described in Subsection (3)(a) shall:
1190	(i) submit to the department:
1191	(A) a fingerprint card in a form acceptable to the Department of Public Safety; and
1192	(B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging
1193	the registration of the prospective agent's fingerprints in the Federal Bureau of
1194	Investigation Next Generation Identification System's Rap Back Service; and
1195	(ii) consent to a fingerprint background check by:
1196	(A) the Bureau of Criminal Identification; and
1197	(B) the Federal Bureau of Investigation.
1198	(c) The Bureau of Criminal Identification shall:
1199	(i) check the fingerprints the prospective agent submits under Subsection (3)(b)
1200	against the applicable state, regional, and national criminal records databases,
1201	including the Federal Bureau of Investigation Next Generation Identification
1202	System;
1203	(ii) report the results of the background check to the department;
1204	(iii) maintain a separate file of fingerprints that prospective agents submit under
1205	Subsection (3)(b) for search by future submissions to the local and regional
1206	criminal records databases, including latent prints;
1207	(iv) request that the fingerprints be retained in the Federal Bureau of Investigation
1208	Next Generation Identification System's Rap Back Service for search by future
1209	submissions to national criminal records databases, including the Next Generation
1210	Identification System and latent prints; and
1211	(v) establish a privacy risk mitigation strategy to ensure that the department only
1212	receives notifications for an individual with whom the department maintains an
1213	authorizing relationship.
1214	(d) The department shall:
1215	(i) assess an individual who submits fingerprints under Subsection (3)(b) a fee in an
1216	amount that the department sets in accordance with Section 63J-1-504 for the
1217	services that the Bureau of Criminal Identification or another authorized agency
1218	provides under this section; and
1219	(ii) remit the fee described in Subsection (3)(d)(i) to the Bureau of Criminal
1220	Identification.

1221	[(4) The department shall designate, on an individual's medical cannabis pharmacy agent
1222	registration card the name of the medical cannabis pharmacy where the individual is
1223	registered as an agent.]
1224	[(5)] (4) A medical cannabis pharmacy agent shall comply with a certification standard that
1225	the department develops in collaboration with the Division of Professional Licensing
1226	and the Board of Pharmacy, or a third-party certification standard that the department
1227	designates by rule, in collaboration with the Division of Professional Licensing and the
1228	Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative
1229	Rulemaking Act.
1230	[(6)] (5) The department shall ensure that the certification standard described in Subsection [
1231	(5)] (4) includes training in:
1232	(a) Utah medical cannabis law; and
1233	(b) medical cannabis pharmacy best practices.
1234	[(7)] (6) The department may revoke the medical cannabis pharmacy agent registration card
1235	of, or refuse to issue a medical cannabis pharmacy agent registration card to, an
1236	individual who:
1237	(a) violates the requirements of this chapter; or
1238	(b) is convicted under state or federal law of:
1239	(i) a felony within the preceding 10 years; or
1240	(ii) after December 3, 2018, a misdemeanor for drug distribution.
1241	[(8)] (7)(a) A medical cannabis pharmacy agent registration card expires two years after
1242	the day on which the department issues or renews the card.
1243	(b) A medical cannabis pharmacy agent may renew the agent's registration card if the
1244	agent:
1245	(i) is eligible for a medical cannabis pharmacy agent registration card under this
1246	section;
1247	(ii) certifies to the department in a renewal application that the information in
1248	Subsection (3)(a) is accurate or updates the information; and
1249	(iii) pays to the department a renewal fee in an amount that:
1250	(A) subject to Subsection 4-41a-104(5), the department sets in accordance with
1251	Section 63J-1-504; and
1252	(B) may not exceed the cost of the relatively lower administrative burden of
1253	renewal in comparison to the original application process.
1254	[(9)] (8)(a) As a condition precedent to registration and renewal of a medical cannabis

1255	pharmacy agent registration card, a medical cannabis pharmacy agent shall:
1256	(i) complete at least one hour of continuing education regarding patient privacy and
1257	federal health information privacy laws that is offered by the department under
1258	Subsection [(9)(b)] (8)(b) or an accredited or approved continuing education
1259	provider that the department recognizes as offering continuing education
1260	appropriate for the medical cannabis pharmacy practice; and
1261	(ii) make a continuing education report to the department in accordance with a
1262	process that the department establishes by rule, in accordance with Title 63G,
1263	Chapter 3, Utah Administrative Rulemaking Act, and in collaboration with the
1264	Division of Professional Licensing and the Board of Pharmacy.
1265	(b) The department may, in consultation with the Division of Professional Licensing,
1266	develop the continuing education described in this Subsection $[(9)]$ (8).
1267	(c) The pharmacist-in-charge described in Section 26B-4-219 shall ensure that each
1268	medical cannabis pharmacy agent working in the medical cannabis pharmacy who
1269	has access to the state electronic verification system is in compliance with this
1270	Subsection [(9)] <u>(8)</u> .
1271	(d) A medical cannabis pharmacy agent may not access the electronic verification
1272	system following the termination of the medical cannabis pharmacy agent's
1273	employment.
1274	[(10)] (9) A medical cannabis pharmacy shall:
1275	(a) maintain a list of employees that have a medical cannabis pharmacy agent
1276	registration card; and
1277	(b) provide the list to the department upon request.
1278	Section 12. Section 4-41a-1202 is amended to read:
1279	4-41a-1202 . Home delivery of medical cannabis shipments Medical cannabis
1280	couriers License.
1281	(1) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1282	Administrative Rulemaking Act, to ensure the safety, security, and efficiency of a home
1283	delivery medical cannabis pharmacy's fulfillment of electronic medical cannabis orders
1284	that the state central patient portal facilitates, including rules regarding the safe and
1285	controlled delivery of medical cannabis shipments.
1286	(2) A person may not operate as a medical cannabis courier without a license that the [
1287	department] licensing board issues under this section.
1288	(3)(a) Subject to Subsections (5) and (6), the [department] licensing board shall issue a

1289	license to operate as a medical cannabis courier to an applicant who is eligible for a
1290	license under this section.
1291	(b) An applicant is eligible for a license under this section if the applicant submits to the [
1292	department] licensing board:
1293	(i) the name and address of an individual who:
1294	(A) has a financial or voting interest of 10% or greater in the proposed medical
1295	cannabis courier; or
1296	(B) has the power to direct or cause the management or control of a proposed
1297	cannabis production establishment;
1298	(ii) an operating plan that includes operating procedures to comply with the operating
1299	requirements for a medical cannabis courier described in this chapter; and
1300	(iii) an application fee in an amount that, subject to Subsection 4-41a-104(5), the
1301	department sets in accordance with Section 63J-1-504.
1302	(4) If the [department] licensing board determines that an applicant is eligible for a license
1303	under this section, the department shall:
1304	(a) charge the applicant an initial license fee in an amount that, subject to Subsection
1305	4-41a-104(5), the department sets in accordance with Section 63J-1-504; and
1306	(b) notify the Department of Public Safety of the license approval and the names of each
1307	individual described in Subsection (3)(b)(i).
1308	(5) The [department] licensing board may not issue a license to operate as a medical
1309	cannabis courier to an applicant if an individual described in Subsection (3)(b)(i):
1310	(a) has been convicted under state or federal law of:
1311	(i) a felony in the preceding 10 years; or
1312	(ii) after September 23, 2019, a misdemeanor for drug distribution; or
1313	(b) is younger than 21 years old.
1314	(6) The [department] licensing board may revoke a license under this part if:
1315	(a) the medical cannabis courier does not begin operations within one year after the day
1316	on which the department issues the initial license;
1317	(b) the medical cannabis courier makes the same violation of this chapter three times;
1318	(c) an individual described in Subsection (3)(b)(i) is convicted, while the license is
1319	active, under state or federal law of:
1320	(i) a felony; or
1321	(ii) after September 23, 2019, a misdemeanor for drug distribution; or
1322	(d) after a change of ownership described in Subsection (14)(c), the [department]

1323	licensing board determines that the medical cannabis courier no longer meets the
1324	minimum standards for licensure and operation of the medical cannabis courier
1325	described in this chapter.
1326	(7) The department shall deposit the proceeds of a fee imposed by this section [in] into the
1327	Qualified Production Enterprise Fund.
1328	(8) The [department's] licensing board's authority to issue a license under this section is
1329	plenary and is not subject to review.
1330	(9) Each applicant for a license as a medical cannabis courier shall submit, at the time of
1331	application, from each individual who has a financial or voting interest of 10% or
1332	greater in the applicant or who has the power to direct or cause the management or
1333	control of the applicant:
1334	(a) a fingerprint card in a form acceptable to the Department of Public Safety;
1335	(b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
1336	registration of the individual's fingerprints in the Federal Bureau of Investigation
1337	Next Generation Identification System's Rap Back Service; and
1338	(c) consent to a fingerprint background check by:
1339	(i) the Bureau of Criminal Identification; and
1340	(ii) the Federal Bureau of Investigation.
1341	(10) The Bureau of Criminal Identification shall:
1342	(a) check the fingerprints the applicant submits under Subsection (9) against the
1343	applicable state, regional, and national criminal records databases, including the
1344	Federal Bureau of Investigation Next Generation Identification System;
1345	(b) report the results of the background check to the department;
1346	(c) maintain a separate file of fingerprints that applicants submit under Subsection (9)
1347	for search by future submissions to the local and regional criminal records databases,
1348	including latent prints;
1349	(d) request that the fingerprints be retained in the Federal Bureau of Investigation Next
1350	Generation Identification System's Rap Back Service for search by future
1351	submissions to national criminal records databases, including the Next Generation
1352	Identification System and latent prints; and
1353	(e) establish a privacy risk mitigation strategy to ensure that the department only
1354	receives notifications for an individual with whom the department maintains an
1355	authorizing relationship.
1356	(11) The department shall:

1357	(a) assess an individual who submits fingerprints under Subsection (9) a fee in an
1358	amount that the department sets in accordance with Section 63J-1-504 for the
1359	services that the Bureau of Criminal Identification or another authorized agency
1360	provides under this section; and
1361	(b) remit the fee described in Subsection (11)(a) to the Bureau of Criminal Identification.
1362	(12) The [department] licensing board shall renew a license under this section every year if,
1363	at the time of renewal:
1364	(a) the licensee meets the requirements of this section; and
1365	(b) the licensee pays the department a license renewal fee in an amount that, subject to
1366	Subsection 4-41a-104(5), the department sets in accordance with Section 63J-1-504.
1367	(13) A person applying for a medical cannabis courier license shall submit to the [
1368	department] licensing board a proposed operating plan that complies with this section
1369	and that includes:
1370	(a) a description of the physical characteristics of any proposed facilities, including a
1371	floor plan and an architectural elevation, and delivery vehicles;
1372	(b) a description of the credentials and experience of each officer, director, or owner of
1373	the proposed medical cannabis courier;
1374	(c) the medical cannabis courier's employee training standards;
1375	(d) a security plan; and
1376	(e) storage and delivery protocols, both short and long term, to ensure that medical
1377	cannabis shipments are stored and delivered in a manner that is sanitary and
1378	preserves the integrity of the cannabis.
1379	(14)(a) A medical cannabis courier license is not transferable or assignable.
1380	(b) A medical cannabis courier shall report in writing to the department no later than $[10]$
1381	45 business days before the date of any change of ownership of the medical cannabis
1382	courier.
1383	(c) If the ownership of a medical cannabis courier changes by 50% or more:
1384	(i) concurrent with the report described in Subsection (14)(b), the medical cannabis
1385	courier shall submit a new application described in Subsection (3)(b);
1386	(ii) within 30 days of the submission of the application, the [department] licensing
1387	board shall:
1388	(A) conduct an application review; and
1389	(B) award a license to the medical cannabis courier for the remainder of the term
1390	of the medical cannabis courier's license before the ownership change if the

1391	medical cannabis courier meets the minimum standards for licensure and
1392	operation of the medical cannabis courier described in this chapter; and
1393	(iii) if the [department] licensing board approves the license application,
1394	notwithstanding Subsection (4), the medical cannabis courier shall pay a license
1395	fee that the department sets in accordance with Section 63J-1-504 in an amount
1396	that covers the [board] licensing board's cost of conducting the application review.
1397	(15)(a) Except as provided in Subsection(15)(b), a person may not advertise regarding
1398	the transportation of medical cannabis.
1399	(b) Notwithstanding Subsection (14)(a) and subject to Section 4-41a-109, a licensed
1400	home delivery medical cannabis pharmacy or a licensed medical cannabis courier
1401	may advertise:
1402	(i) a green cross;
1403	(ii) the pharmacy's or courier's name and logo; and
1404	(iii) that the pharmacy or courier is licensed to transport medical cannabis shipments.
1405	Section 13. Section 4-41a-1204 is amended to read:
1406	4-41a-1204 . Medical cannabis courier agent Background check Registration
1407	card Rebuttable presumption.
1408	(1) An individual may not serve as a medical cannabis courier agent unless the department
1409	registers the individual as a medical cannabis courier agent.
1410	(2)(a) The department shall, within 15 days after the day on which the department
1411	receives a complete application from a medical cannabis courier on behalf of a
1412	medical cannabis courier agent, register and issue a medical cannabis courier agent
1413	registration card to the prospective agent if the medical cannabis courier:
1414	(i) provides to the department:
1415	(A) the prospective agent's name and address;
1416	(B) the name and address of the medical cannabis courier;
1417	(C) the name and address of each home delivery medical cannabis pharmacy with
1418	which the medical cannabis courier contracts to deliver medical cannabis
1419	shipments; and
1420	(D) the submission required under Subsection (2)(b);
1421	(ii) as reported under Subsection (2)(c), has not been convicted under state or federal
1422	law of:
1423	(A) a felony in the last 10 years; or
1424	(B) after December 3, 2018, a misdemeanor for drug distribution; and

1425	(iii) pays the department a fee in an amount that, subject to Subsection 4-41a-104(5),
1426	the department sets in accordance with Section 63J-1-504.
1427	(b) Each prospective agent described in Subsection (2)(a) shall:
1428	(i) submit to the department:
1429	(A) a fingerprint card in a form acceptable to the Department of Public Safety; and
1430	(B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging
1431	the registration of the prospective agent's fingerprints in the Federal Bureau of
1432	Investigation Next Generation Identification System's Rap Back Service; and
1433	(ii) consent to a fingerprint background check by:
1434	(A) the Bureau of Criminal Identification; and
1435	(B) the Federal Bureau of Investigation.
1436	(c) The Bureau of Criminal Identification shall:
1437	(i) check the fingerprints the prospective agent submits under Subsection (2)(b)
1438	against the applicable state, regional, and national criminal records databases,
1439	including the Federal Bureau of Investigation Next Generation Identification
1440	System;
1441	(ii) report the results of the background check to the department;
1442	(iii) maintain a separate file of fingerprints that prospective agents submit under
1443	Subsection (2)(b) for search by future submissions to the local and regional
1444	criminal records databases, including latent prints;
1445	(iv) request that the fingerprints be retained in the Federal Bureau of Investigation
1446	Next Generation Identification System's Rap Back Service for search by future
1447	submissions to national criminal records databases, including the Next Generation
1448	Identification System and latent prints; and
1449	(v) establish a privacy risk mitigation strategy to ensure that the department only
1450	receives notifications for an individual with whom the department maintains an
1451	authorizing relationship.
1452	(d) The department shall:
1453	(i) assess an individual who submits fingerprints under Subsection (2)(b) a fee in an
1454	amount that the department sets in accordance with Section 63J-1-504 for the
1455	services that the Bureau of Criminal Identification or another authorized agency
1456	provides under this section; and
1457	(ii) remit the fee described in Subsection (2)(d)(i) to the Bureau of Criminal
1458	Identification.

1459	[(3) The department shall designate on an individual's medical cannabis courier agent
1460	registration card the name of the medical cannabis pharmacy where the individual is
1461	registered as an agent and each home delivery medical cannabis courier for which the
1462	medical cannabis courier delivers medical cannabis shipments.]
1463	[(4)] (3)(a) A medical cannabis courier agent shall comply with a certification standard
1464	that the department develops, in collaboration with the Division of Professional
1465	Licensing and the Board of Pharmacy, or a third-party certification standard that the
1466	department designates by rule in collaboration with the Division of Professional
1467	Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3,
1468	Utah Administrative Rulemaking Act.
1469	(b) The department shall ensure that the certification standard described in Subsection [
1470	(4)(a)] (3)(a) includes training in:
1471	(i) Utah medical cannabis law;
1472	(ii) the medical cannabis shipment process; and
1473	(iii) medical cannabis courier agent best practices.
1474	[(5)] (4)(a) A medical cannabis courier agent registration card expires two years after the
1475	day on which the department issues or renews the card.
1476	(b) A medical cannabis courier agent may renew the agent's registration card if the agent:
1477	(i) is eligible for a medical cannabis courier agent registration card under this section;
1478	(ii) certifies to the department in a renewal application that the information in
1479	Subsection (2)(a) is accurate or updates the information; and
1480	(iii) pays to the department a renewal fee in an amount that:
1481	(A) subject to Subsection 4-41a-104(5), the department sets in accordance with
1482	Section 63J-1-504; and
1483	(B) may not exceed the cost of the relatively lower administrative burden of
1484	renewal in comparison to the original application process.
1485	[(6)] (5) The department may revoke or refuse to issue or renew the medical cannabis
1486	courier agent registration card of an individual who:
1487	(a) violates the requirements of this chapter; or
1488	(b) is convicted under state or federal law of:
1489	(i) a felony within the preceding 10 years; or
1490	(ii) after December 3, 2018, a misdemeanor for drug distribution.
1491	[(7)] (6) A medical cannabis courier agent whom the department has registered under this
1492	section shall carry the agent's medical cannabis courier agent registration card with the

1493	agent at all times when:
1494	(a) the agent is on the premises of the medical cannabis courier, a medical cannabis
1495	pharmacy, or a delivery address; and
1496	(b) the agent is handling a medical cannabis shipment.
1497	[(8)] (7) If a medical cannabis courier agent handling a medical cannabis shipment
1498	possesses the shipment in compliance with Subsection $[(7)]$ (6):
1499	(a) there is a rebuttable presumption that the agent possesses the shipment legally; and
1500	(b) there is no probable cause, based solely on the agent's possession of the medical
1501	cannabis shipment that the agent is engaging in illegal activity.
1502	[(9)] (8)(a) A medical cannabis courier agent who violates Subsection $[(7)]$ (6) is:
1503	(i) guilty of an infraction; and
1504	(ii) subject to a \$100 fine.
1505	(b) An individual who is guilty of a violation described in Subsection $[(9)(a)]$ (8)(a) is
1506	not guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for
1507	the conduct underlying the violation described in Subsection $[(9)(a)]$ (8)(a).
1508	[(10)] (9) A medical cannabis courier shall:
1509	(a) maintain a list of employees who have a medical cannabis courier agent card; and
1510	(b) provide the list to the department upon request.
1511	Section 14. Section 26B-1-435 is amended to read:
1512	26B-1-435 . Medical Cannabis Policy Advisory Board creation Membership
1513	Duties.
1514	(1) There is created within the department the Medical Cannabis Policy Advisory Board.
1515	(2)(a) The advisory board shall consist of the following members:
1516	(i) appointed by the executive director:
1517	(A) a qualified medical provider who has recommended medical cannabis to at
1518	least 100 patients before being appointed;
1519	(B) a medical research professional;
1520	(C) a mental health specialist;
1521	(D) an individual who represents an organization that advocates for medical
1522	cannabis patients;
1523	(E) an individual who holds a medical cannabis patient card; and
1524	(F) a member of the general public who does not hold a medical cannabis card; and
1525	(ii) appointed by the commissioner of the Department of Agriculture and Food:
1526	(A) an individual who owns or operates a licensed cannabis cultivation facility, as

1527	defined in Section 4-41a-102;
1528	(B) an individual who owns or operates a licensed medical cannabis pharmacy;
1529	and
1530	(C) a law enforcement officer.
1531	(b) The commissioner of the Department of Agriculture and Food shall ensure that at
1532	least one individual appointed under Subsection (2)(a)(ii)(A) or (B) also owns or
1533	operates a licensed cannabis processing facility.
1534	(3)(a) Subject to Subsection (3)(b), a member of the advisory board shall serve for a
1535	four year term.
1536	(b) When appointing the initial membership of the advisory board, the executive director
1537	and the commissioner of the Department of Agriculture and Food shall coordinate to
1538	appoint four advisory board members to serve a term of two years to ensure that
1539	approximately half of the board is appointed every two years.
1540	(4)(a) If an advisory board member is no longer able to serve as a member, a new
1541	member shall be appointed in the same manner as the original appointment.
1542	(b) A member appointed in accordance with Subsection (4)(a) shall serve for the
1543	remainder of the unexpired term of the original appointment.
1544	(5)(a) A majority of the advisory board members constitutes a quorum.
1545	(b) The action of a majority of a quorum constitutes an action of the advisory board.
1546	(c) For a term lasting one year, the advisory board shall annually designate members of
1547	the advisory board to serve as chair and vice-chair.
1548	(d) When designating the chair and vice-chair, the advisory board shall ensure that at
1549	least one individual described Subsection (2)(a)(i) is appointed as chair or vice-chair.
1550	(6) An advisory board member may not receive compensation or benefits for the member's
1551	service on the advisory board but may receive per diem and reimbursement for travel
1552	expenses incurred as an advisory board member in accordance with:
1553	(a) Sections 63A-3-106 and 63A-3-107; and
1554	(b) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
1555	63A-3-107.
1556	(7) The department shall:
1557	(a) provide staff support for the advisory board; and
1558	(b) assist the advisory board in conducting meetings.
1559	(8) The advisory board may recommend:

1560 (a) to the department or the Department of Agriculture and Food changes to current or

1561	proposed medical cannabis rules or statutes; and
1562	(b) to the appropriate legislative committee whether the advisory board supports a
1563	change to medical cannabis statutes.
1564	(9) The advisory board shall:
1565	(a) review any draft rule that is authorized under [this chapter] Chapter 4, Part 2,
1566	Cannabinoid Research and Medical Cannabis, or Title 4, Chapter 41a, Cannabis
1567	Production Establishments and Pharmacies;
1568	(b) consult with the Department of Agriculture and Food regarding the issuance of an
1569	additional:
1570	(i) cultivation facility license under Section 4-41a-205; or
1571	(ii) pharmacy license under Section 4-41a-1005;
1572	(c) consult with the department regarding cannabis patient education;
1573	(d) consult regarding the reasonableness of any fees set by the department or the
1574	Department of Agriculture and Food that pertain to the medical cannabis program;
1575	and
1576	(e) consult regarding any issue pertaining to medical cannabis when asked by the
1577	department or the Utah Department of Agriculture and Food.
1578	Section 15. Section 26B-4-202 is amended to read:
1579	26B-4-202 . Electronic verification system.
1580	(1) The Department of Agriculture and Food, the department, the Department of Public
1581	Safety, and the Division of Technology Services shall:
1582	(a) enter into a memorandum of understanding in order to determine the function and
1583	operation of the state electronic verification system in accordance with Subsection
1584	(2);
1585	(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah
1586	Procurement Code, to develop a request for proposals for a third-party provider to
1587	develop and maintain the state electronic verification system in coordination with the
1588	Division of Technology Services; and
1589	(c) select a third-party provider who:
1590	(i) meets the requirements contained in the request for proposals issued under
1591	Subsection (1)(b); and
1592	(ii) may not have any commercial or ownership interest in a cannabis production
1593	establishment or a medical cannabis pharmacy.
1594	(2) The Department of Agriculture and Food, the department, the Department of Public

1595	Safety, and the Division of Technology Services shall ensure that the state electronic
1596	verification system described in Subsection (1):
1597	(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a
1598	medical cannabis guardian card, provided that the card may not become active until:
1599	(i) the relevant qualified medical provider completes the associated medical cannabis
1600	recommendation; or
1601	(ii) for a medical cannabis card related to a limited medical provider's
1602	recommendation, the medical cannabis pharmacy completes the recording
1603	described in Subsection (2)(d);
1604	(b) allows an individual to apply to renew a medical cannabis patient card or a medical
1605	cannabis guardian card in accordance with Section 26B-4-213;
1606	(c) allows a qualified medical provider, or an employee described in Subsection (3)
1607	acting on behalf of the qualified medical provider, to:
1608	(i) access dispensing and card status information regarding a patient:
1609	(A) with whom the qualified medical provider has a provider-patient relationship;
1610	and
1611	(B) for whom the qualified medical provider has recommended or is considering
1612	recommending a medical cannabis card;
1613	(ii) electronically recommend treatment with cannabis in a medicinal dosage form or
1614	a cannabis product in a medicinal dosage form and optionally recommend dosing
1615	guidelines;
1616	(iii) electronically renew a recommendation to a medical cannabis patient cardholder
1617	or medical cannabis guardian cardholder:
1618	(A) using telehealth services, for the qualified medical provider who originally
1619	recommended a medical cannabis treatment during a face-to-face visit with the
1620	patient; or
1621	(B) during a face-to-face visit with the patient, for a qualified medical provider
1622	who did not originally recommend the medical cannabis treatment during a
1623	face-to-face visit; and
1624	(iv) submit an initial application, renewal application, or application payment on
1625	behalf of an individual applying for any of the following:
1626	(A) a medical cannabis patient card;
1627	(B) a medical cannabis guardian card; or
1628	(C) a medical cannabis caregiver card;

1629	(d) allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy
1630	agent, in accordance with Subsection 4-41a-1101(10)(a), to:
1631	(i) access the electronic verification system to review the history within the system of
1632	a patient with whom the provider or agent is interacting, limited to read-only
1633	access for medical cannabis pharmacy agents unless the medical cannabis
1634	pharmacy's pharmacist in charge authorizes add and edit access;
1635	(ii) record a patient's recommendation from a limited medical provider, including any
1636	directions of use, dosing guidelines, or caregiver indications from the limited
1637	medical provider;
1638	(iii) record a limited medical provider's renewal of the provider's previous
1639	recommendation; and
1640	(iv) submit an initial application, renewal application, or application payment on
1641	behalf of an individual applying for any of the following:
1642	(A) a medical cannabis patient card;
1643	(B) a medical cannabis guardian card; or
1644	(C) a medical cannabis caregiver card;
1645	(e) connects with:
1646	(i) an inventory control system that a medical cannabis pharmacy uses to track in real
1647	time and archive purchases of any cannabis in a medicinal dosage form, cannabis
1648	product in a medicinal dosage form, or a medical cannabis device, including:
1649	(A) the time and date of each purchase;
1650	(B) the quantity and type of cannabis, cannabis product, or medical cannabis
1651	device purchased;
1652	(C) any cannabis production establishment, any medical cannabis pharmacy, or
1653	any medical cannabis courier associated with the cannabis, cannabis product,
1654	or medical cannabis device; and
1655	(D) the personally identifiable information of the medical cannabis cardholder
1656	who made the purchase; and
1657	(ii) any commercially available inventory control system that a cannabis production
1658	establishment utilizes in accordance with Section 4-41a-103 to use data that the
1659	Department of Agriculture and Food requires by rule, in accordance with Title
1660	63G, Chapter 3, Utah Administrative Rulemaking Act, from the inventory
1661	tracking system that a licensee uses to track and confirm compliance;
1662	(f) provides access to:

1663	(i) the department to the extent necessary to carry out the department's functions and
1664	responsibilities under this part;
1665	(ii) the Department of Agriculture and Food to the extent necessary to carry out the
1666	functions and responsibilities of the Department of Agriculture and Food under
1667	Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies; and
1668	(iii) the Division of Professional Licensing to the extent necessary to carry out the
1669	functions and responsibilities related to the participation of the following in the
1670	recommendation and dispensing of medical cannabis:
1671	(A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing
1672	Act;
1673	(B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
1674	(C) an advanced practice registered nurse licensed under Title 58, Chapter 31b,
1675	Nurse Practice Act;
1676	(D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
1677	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
1678	(E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1679	Assistant Act;
1680	(g) provides access to and interaction with the state central patient portal;
1681	(h) communicates dispensing information from a record that a medical cannabis
1682	pharmacy submits to the state electronic verification system under Subsection
1683	4-41a-1102(3)(a)(ii) to the controlled substance database;
1684	(i) provides access to state or local law enforcement only to verify the validity of an
1685	individual's medical cannabis card for the administration of criminal justice and
1686	through a database used by law enforcement; and
1687	(j) creates a record each time a person accesses the system that identifies the person who
1688	accesses the system and the individual whose records the person accesses.
1689	(3)(a) An employee of a qualified medical provider may access the electronic
1690	verification system for a purpose described in Subsection (2)(c) on behalf of the
1691	qualified medical provider if:
1692	(i) the qualified medical provider has designated the employee as an individual
1693	authorized to access the electronic verification system on behalf of the qualified
1694	medical provider;
1695	(ii) the qualified medical provider provides written notice to the department of the
1696	employee's identity and the designation described in Subsection (3)(a)(i); and

1697	(iii) the department grants to the employee access to the electronic verification
1698	system.
1699	(b) An employee of a business that employs a qualified medical provider may access the
1700	electronic verification system for a purpose described in Subsection (2)(c) on behalf
1701	of the qualified medical provider if:
1702	(i) the qualified medical provider has designated the employee as an individual
1703	authorized to access the electronic verification system on behalf of the qualified
1704	medical provider;
1705	(ii) the qualified medical provider and the employing business jointly provide written
1706	notice to the department of the employee's identity and the designation described
1707	in Subsection (3)(b)(i); and
1708	(iii) the department grants to the employee access to the electronic verification
1709	system.
1710	(c) Each year, an employee described in Subsections (3)(a) and (3)(b) shall complete at
1711	least one hour of education regarding health information privacy laws that is offered
1712	by the department or an accredited or approved education provider that the
1713	department recognizes before the department may grant the employee access to the
1714	electronic verification system.
1715	(4)(a) As used in this Subsection (4), "prescribing provider" means:
1716	(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
1717	(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1718	Practice Act;
1719	(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
1720	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
1721	(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1722	Assistant Act.
1723	(b) A prescribing provider may access information in the electronic verification system
1724	regarding a patient the prescribing provider treats.
1725	(5) The department may release limited data that the system collects for the purpose of:
1726	(a) conducting medical and other department approved research;
1727	(b) providing the report required by Section 26B-4-222; and
1728	(c) other official department purposes.
1729	(6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1730	Administrative Rulemaking Act, to establish:

S.B. 64

1731	(a) the limitations on access to the data in the state electronic verification system as
1732	described in this section; and
1733	(b) standards and procedures to ensure accurate identification of an individual requesting
1734	information or receiving information in this section.
1735	(7) Any person who negligently or recklessly releases any information in the state
1736	electronic verification system in violation of this section is guilty of a class C
1737	misdemeanor.
1738	(8) Any person who obtains or attempts to obtain information from the state electronic
1739	verification system by misrepresentation or fraud is guilty of a third degree felony.
1740	(9)(a) Except as provided in Subsections (9)(c) and (9)(e), a person may not knowingly
1741	and intentionally use, release, publish, or otherwise make available to any other
1742	person information obtained from the state electronic verification system for any
1743	purpose other than a purpose specified in this section.
1744	(b) Each separate violation of this Subsection (9) is:
1745	(i) a third degree felony; and
1746	(ii) subject to a civil penalty not to exceed \$5,000.
1747	(c) A law enforcement officer who uses the database used by law enforcement to access
1748	information in the electronic verification system for a reason that is not the
1749	administration of criminal justice is guilty of a class B misdemeanor.
1750	(d) The department shall determine a civil violation of this Subsection (9) in accordance
1751	with Title 63G, Chapter 4, Administrative Procedures Act.
1752	(e) Civil penalties assessed under this Subsection (9) shall be deposited into the General
1753	Fund.
1754	(f) This Subsection (9) does not prohibit a person who obtains information from the state
1755	electronic verification system under Subsection (2)(a), (c), or (f) from:
1756	(i) including the information in the person's medical chart or file for access by a
1757	person authorized to review the medical chart or file;
1758	(ii) providing the information to a person in accordance with the requirements of the
1759	Health Insurance Portability and Accountability Act of 1996; or
1760	(iii) discussing or sharing that information about the patient with the patient.
1761	Section 16. Section 26B-4-204 is amended to read:
1762	26B-4-204 . Qualified medical provider registration Continuing education
1763	Treatment recommendation Limited medical provider.
1764	(1)(a)(i) Except as provided in Subsection (1)(b), an individual may not recommend

1765	a medical cannabis treatment unless the department registers the individual as a
1766	qualified medical provider in accordance with this section.
1767	(ii) Notwithstanding Subsection (1)(a)(i), a qualified medical provider who is
1768	podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act,
1769	may not recommend a medical cannabis treatment except within the course and
1770	scope of a practice of podiatry, as that term is defined in Section 58-5a-102.
1771	(b) An individual who meets the recommending qualifications may recommend a
1772	medical cannabis treatment as a limited medical provider without registering under
1773	Subsection (1)(a) if:
1774	(i) the individual recommends the use of medical cannabis to the patient through an
1775	order described in Subsection (1)(c) after:
1776	(A) a face-to-face visit for an initial recommendation or the renewal of a
1777	recommendation for a patient for whom the limited medical provider did not
1778	make the patient's original recommendation; or
1779	(B) a visit using telehealth services for a renewal of a recommendation for a
1780	patient for whom the limited medical provider made the patient's original
1781	recommendation; and
1782	(ii) the individual's recommendation or renewal would not cause the total number of
1783	the individual's patients who have a valid medical cannabis patient card or
1784	provisional patient card resulting from the individual's recommendation to exceed
1785	15.
1786	(c) The individual described in Subsection (1)(b) shall communicate the individual's
1787	recommendation through an order for the medical cannabis pharmacy to record the
1788	individual's recommendation or renewal in the state electronic verification system
1789	under the individual's recommendation that:
1790	(i)(A) the individual or the individual's employee sends electronically to a
1791	medical cannabis pharmacy; or
1792	(B) the individual gives to the patient in writing for the patient to deliver to a
1793	medical cannabis pharmacy; and
1794	(ii) may include:
1795	(A) directions of use or dosing guidelines; and
1796	(B) an indication of a need for a caregiver in accordance with Subsection [
1797	26B-4-213(3)(c)] <u>26B-4-213(3)(b)</u> .
1798	(d) If the limited medical provider gives the patient a written recommendation to deliver

1799	to a medical cannabis pharmacy under Subsection (1)(c)(i)(B), the limited medical
1800	provider shall ensure that the document includes all of the information that is
1801	included on a prescription the provider would issue for a controlled substance,
1802	including:
1803	(i) the date of issuance;
1804	(ii) the provider's name, address and contact information, controlled substance license
1805	information, and signature; and
1806	(iii) the patient's name, address and contact information, age, and diagnosed
1807	qualifying condition.
1808	(e) In considering making a recommendation as a limited medical provider, an
1809	individual may consult information that the department makes available on the
1810	department's website for recommending providers.
1811	(2)(a) The department shall, within 15 days after the day on which the department
1812	receives an application from an individual, register and issue a qualified medical
1813	provider registration card to the individual if the individual:
1814	(i) provides to the department the individual's name and address;
1815	(ii) provides to the department an acknowledgment that the individual has completed
1816	four hours of continuing education related to medical cannabis;
1817	(iii) provides to the department evidence that the individual meets the recommending
1818	qualifications;
1819	(iv) for an applicant on or after November 1, 2021, provides to the department the
1820	information described in Subsection (10)(a); and
1821	(v) pays the department a fee in an amount that:
1822	(A) the department sets, in accordance with Section 63J-1-504; and
1823	(B) does not exceed \$300 for an initial registration.
1824	(b) The department may not register an individual as a qualified medical provider if the
1825	individual is:
1826	(i) a pharmacy medical provider; or
1827	(ii) an owner, officer, director, board member, employee, or agent of a cannabis
1828	production establishment, a medical cannabis pharmacy, or a medical cannabis
1829	courier.
1830	(3)(a) An individual shall complete the continuing education related to medical
1831	cannabis in the following amounts:
1832	(i) for an individual as a condition precedent to registration, four hours; and

S.B. 64

1833	(ii) for a qualified medical provider as a condition precedent to renewal, four hours
1834	every two years.
1835	(b) The department may, in consultation with the Division of Professional Licensing,
1836	develop continuing education related to medical cannabis.
1837	(c) The continuing education described in this Subsection (3) may discuss:
1838	(i) the provisions of this part;
1839	(ii) general information about medical cannabis under federal and state law;
1840	(iii) the latest scientific research on the endocannabinoid system and medical
1841	cannabis, including risks and benefits;
1842	(iv) recommendations for medical cannabis as it relates to the continuing care of a
1843	patient in pain management, risk management, potential addiction, or palliative
1844	care; and
1845	(v) best practices for recommending the form and dosage of medical cannabis based
1846	on the qualifying condition underlying a medical cannabis recommendation.
1847	(4)(a) Except as provided in Subsection (4)(b), a qualified medical provider may not
1848	recommend a medical cannabis treatment to more than 1.5% of the total amount of
1849	medical cannabis patient cardholders.
1850	(b) If a qualified medical provider receives payment from an insurance plan for services
1851	provided under this chapter, then the patient whose insurance plan was billed does
1852	not count toward the 1.5% patient cap described in Subsection (4)(a).
1853	(5) A recommending medical provider may recommend medical cannabis to an individual
1854	under this part only in the course of a provider-patient relationship after the
1855	recommending medical provider has completed and documented in the patient's medical
1856	record a thorough assessment of the patient's condition and medical history based on the
1857	appropriate standard of care for the patient's condition.
1858	(6)(a) Except as provided in Subsections (6)(b) and (c), a person may not advertise that
1859	the person or the person's employee recommends a medical cannabis treatment.
1860	(b) Notwithstanding Subsection (6)(a) and Section 4-41a-109, a qualified medical
1861	provider, medical clinic, or medical office that employs a qualified medical provider
1862	may advertise only the following:
1863	(i) a green cross;
1864	(ii) the provider's or clinic's name and logo;
1865	(iii) a qualifying condition that the individual treats;
1866	(iv) that the qualified medical provider, medical clinic, or medical office evaluates

1867	patients for medical cannabis recommendations;
1868	(v) a scientific study regarding medical cannabis use; or
1869	(vi) contact information.
1870	(c) Notwithstanding Subsection (6)(a) and Section 4-41a-109, qualified medical
1871	provider, medical clinic, or medical office that employs a qualified medical provider
1872	may engage in targeted marketing, as determined by the department through rule, for
1873	advertising medical cannabis recommendation services.
1874	(7)(a) A qualified medical provider registration card expires two years after the day on
1875	which the department issues the card.
1876	(b) The department shall renew a qualified medical provider's registration card if the
1877	provider:
1878	(i) applies for renewal;
1879	(ii) is eligible for a qualified medical provider registration card under this section,
1880	including maintaining an unrestricted license under the recommending
1881	qualifications;
1882	(iii) certifies to the department in a renewal application that the information in
1883	Subsection (2)(a) is accurate or updates the information;
1884	(iv) submits a report detailing the completion of the continuing education
1885	requirement described in Subsection (3); and
1886	(v) pays the department a fee in an amount that:
1887	(A) the department sets, in accordance with Section 63J-1-504; and
1888	(B) does not exceed \$50 for a registration renewal.
1889	(8) The department may revoke the registration of a qualified medical provider who fails to
1890	maintain compliance with the requirements of this section.
1891	(9) A recommending medical provider may not:
1892	(a) receive any compensation or benefit for the qualified medical provider's medical
1893	cannabis treatment recommendation from:
1894	(i) a cannabis production establishment or an owner, officer, director, board member,
1895	employee, or agent of a cannabis production establishment;
1896	(ii) a medical cannabis pharmacy or an owner, officer, director, board member,
1897	employee, or agent of a medical cannabis pharmacy; or
1898	(iii) a recommending medical provider or pharmacy medical provider; or
1899	(b) provide a medical cannabis recommendation at a medical clinic or medical office
1900	that is violating the advertising limitations described in Subsection (6).

1901	(10)(a) Each quarter, a qualified medical provider shall report to the department, in a
1902	manner designated by the department:
1903	(i) if applicable, that the qualified medical provider or the entity that employs the
1904	qualified medical provider represents online or on printed material that the
1905	qualified medical provider is a qualified medical provider or offers medical
1906	cannabis recommendations to patients; and
1907	(ii)(A) for cash payment without insurance, the fee amount that the qualified
1908	medical provider or the entity that employs the qualified medical provider
1909	charges a patient for a medical cannabis recommendation as an actual cash
1910	rate; and
1911	(B) whether the qualified medical provider or the entity that employs the qualified
1912	medical provider bills insurance.
1913	(b) The department shall:
1914	(i) ensure that the following information related to qualified medical providers and
1915	entities described in Subsection (10)(a)(i) is available on the department's website
1916	or on the health care price transparency tool under Subsection (10)(b)(ii):
1917	(A) the name of the qualified medical provider and, if applicable, the name of the
1918	entity that employs the qualified medical provider;
1919	(B) the address of the qualified medical provider's office or, if applicable, the
1920	entity that employs the qualified medical provider; and
1921	(C) the fee amount described in Subsection (10)(a)(ii)(A); and
1922	(ii) share data collected under this Subsection (10) with the state auditor for use in the
1923	health care price transparency tool described in Section 67-3-11.
1924	Section 17. Section 26B-4-213 is amended to read:
1925	26B-4-213 . Medical cannabis patient card Medical cannabis guardian card
1926	Conditional medical cannabis card Application Fees Studies.
1927	(1)(a) Subject to Section 26B-4-246, within 15 days after the day on which an
1928	individual who satisfies the eligibility criteria in this section or Section 26B-4-214
1929	submits an application in accordance with this section or Section 26B-4-214, the
1930	department shall:
1931	(i) issue a medical cannabis patient card to an individual described in Subsection
1932	(2)(a);
1933	(ii) issue a medical cannabis guardian card to an individual described in Subsection
1934	(2)(b);

1935	(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
1936	(iv) issue a medical cannabis caregiver card to an individual described in Subsection
1937	26B-4-214(4).
1938	(b)(i) Upon the entry of a recommending medical provider's medical cannabis
1939	recommendation for a patient in the state electronic verification system, either by
1940	the provider or the provider's employee or by a medical cannabis pharmacy
1941	medical provider or medical cannabis pharmacy in accordance with Subsection
1942	4-41a-1101(10)(a), the department shall issue to the patient an electronic
1943	conditional medical cannabis card, in accordance with this Subsection (1)(b).
1944	(ii) A conditional medical cannabis card is valid for the lesser of:
1945	(A) 60 days; or
1946	(B) the day on which the department completes the department's review and issues
1947	a medical cannabis card under Subsection (1)(a), denies the patient's medical
1948	cannabis card application, or revokes the conditional medical cannabis card
1949	under Subsection (8).
1950	(iii) The department may issue a conditional medical cannabis card to an individual
1951	applying for a medical cannabis patient card for which approval of the
1952	Compassionate Use Board is not required.
1953	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1954	obligations under law applicable to a holder of the medical cannabis card for
1955	which the individual applies and for which the department issues the conditional
1956	medical cannabis card.
1957	(2)(a) An individual is eligible for a medical cannabis patient card if:
1958	(i)(A) the individual is at least 21 years old; or
1959	(B) the individual is 18, 19, or 20 years old, the individual petitions the
1960	Compassionate Use Board under Section 26B-1-421, and the Compassionate
1961	Use Board recommends department approval of the petition;
1962	(ii) the individual is a Utah resident;
1963	(iii) the individual's recommending medical provider recommends treatment with
1964	medical cannabis in accordance with Subsection (4);
1965	(iv) the individual signs an acknowledgment stating that the individual received the
1966	information described in Subsection (9); and
1967	(v) the individual pays to the department a fee in an amount that, subject to
1968	Subsection 26B-1-310(5), the department sets in accordance with Section

1969	63J-1-504.
1970	(b)(i) An individual is eligible for a medical cannabis guardian card if the individual:
1971	(A) is at least 18 years old;
1972	(B) is a Utah resident;
1973	(C) is the parent or legal guardian of a minor for whom the minor's recommending
1974	medical provider recommends a medical cannabis treatment, the individual
1975	petitions the Compassionate Use Board under Section 26B-1-421, and the
1976	Compassionate Use Board recommends department approval of the petition;
1977	(D) the individual signs an acknowledgment stating that the individual received
1978	the information described in Subsection (9); and
1979	(E) pays to the department a fee in an amount that, subject to Subsection
1980	26B-1-310(5), the department sets in accordance with Section 63J-1-504, plus
1981	the cost of the criminal background check described in Section 26B-4-215.
1982	(ii) The department shall notify the Department of Public Safety of each individual
1983	that the department registers for a medical cannabis guardian card.
1984	(c)(i) A minor is eligible for a provisional patient card if:
1985	(A) the minor has a qualifying condition;
1986	(B) the minor's recommending medical provider recommends a medical cannabis
1987	treatment to address the minor's qualifying condition;
1988	(C) one of the minor's parents or legal guardians petitions the Compassionate Use
1989	Board under Section 26B-1-421, and the Compassionate Use Board
1990	recommends department approval of the petition; and
1991	(D) the minor's parent or legal guardian is eligible for a medical cannabis guardian
1992	card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d)
1993	who is eligible for a medical cannabis caregiver card under Section 26B-4-214.
1994	(ii) The department shall automatically issue a provisional patient card to the minor
1995	described in Subsection (2)(c)(i) at the same time the department issues a medical
1996	cannabis guardian card to the minor's parent or legal guardian.
1997	(d) If the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A)
1998	through (C) does not qualify for a medical cannabis guardian card under Subsection
1999	(2)(b), the parent or legal guardian may designate up to two caregivers in accordance
2000	with Subsection 26B-4-214(1)(c) to ensure that the minor has adequate and safe
2001	access to the recommended medical cannabis treatment.
2002	(3)(a) An individual who is eligible for a medical cannabis card described in Subsection

2003	(2)(a) or (b) shall submit an application for a medical cannabis card to the department:
2004	(i) through an electronic application connected to the state electronic verification
2005	system;
2006	(ii) with the recommending medical provider; and
2007	(iii) with information including:
2008	(A) the applicant's name, gender, age, and address;
2009	(B) the number of the applicant's government issued photo identification;
2010	(C) for a medical cannabis guardian card, the name, gender, and age of the minor
2011	receiving a medical cannabis treatment under the cardholder's medical cannabis
2012	guardian card; and
2013	(D) for a provisional patient card, the name of the minor's parent or legal guardian
2014	who holds the associated medical cannabis guardian card.
2015	[(b) The department shall ensure that a medical cannabis card the department issues
2016	under this section contains the information described in Subsection (3)(a)(iii).]
2017	[(c)] (b)(i) If a recommending medical provider determines that, because of age,
2018	illness, or disability, a medical cannabis patient cardholder requires assistance in
2019	administering the medical cannabis treatment that the recommending medical
2020	provider recommends, the recommending medical provider may indicate the
2021	cardholder's need in the state electronic verification system, either directly or, for
2022	a limited medical provider, through the order described in Subsections 26B-4-204
2023	(1)(c) and (d).
2024	(ii) If a recommending medical provider makes the indication described in
2025	Subsection $[(3)(c)(i)]$ (3)(b)(i):
2026	(A) the department shall add a label to the relevant medical cannabis patient card
2027	indicating the cardholder's need for assistance;
2028	(B) any adult who is 18 years old or older and who is physically present with the
2029	cardholder at the time the cardholder needs to use the recommended medical
2030	cannabis treatment may handle the medical cannabis treatment and any
2031	associated medical cannabis device as needed to assist the cardholder in
2032	administering the recommended medical cannabis treatment; and
2033	(C) an individual of any age who is physically present with the cardholder in the
2034	event of an emergency medical condition, as that term is defined in Section
2035	31A-1-301, may handle the medical cannabis treatment and any associated
2036	medical cannabis device as needed to assist the cardholder in administering the

2037	recommended medical cannabis treatment.
2038	(iii) A non-cardholding individual acting under Subsection [(3)(c)(ii)(B)] (3)(b)(ii)(B)
2039	or (C) may not:
2040	(A) ingest or inhale medical cannabis;
2041	(B) possess, transport, or handle medical cannabis or a medical cannabis device
2042	outside of the immediate area where the cardholder is present or with an intent
2043	other than to provide assistance to the cardholder; or
2044	(C) possess, transport, or handle medical cannabis or a medical cannabis device
2045	when the cardholder is not in the process of being dosed with medical cannabis.
2046	(4) To recommend a medical cannabis treatment to a patient or to renew a recommendation,
2047	a recommending medical provider shall:
2048	(a) visit with the patient face-to-face for an initial recommendation unless the patient:
2049	(i) prefers a virtual visit; and
2050	(ii)(A) is on hospice or has a terminal illness according to the patient's medical
2051	provider; or
2052	(B) is a resident of an assisted living facility, as defined in Section 26B-2-201, or
2053	a nursing care facility, as defined in Section 26B-2-201;
2054	(b) before recommending or renewing a recommendation for medical cannabis in a
2055	medicinal dosage form or a cannabis product in a medicinal dosage form:
2056	(i) verify the patient's and, for a minor patient, the minor patient's parent or legal
2057	guardian's government issued photo identification described in Subsection (3)(a);
2058	(ii) review any record related to the patient and, for a minor patient, the patient's
2059	parent or legal guardian in:
2060	(A) for a qualified medical provider, the state electronic verification system; and
2061	(B) the controlled substance database created in Section 58-37f-201; and
2062	(iii) consider the recommendation in light of the patient's qualifying condition,
2063	history of substance use or opioid use disorder, and history of medical cannabis
2064	and controlled substance use during a visit with the patient; and
2065	(c) state in the recommending medical provider's recommendation that the patient:
2066	(i) suffers from a qualifying condition, including the type of qualifying condition; and
2067	(ii) may benefit from treatment with cannabis in a medicinal dosage form or a
2068	cannabis product in a medicinal dosage form.
2069	(5)(a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the
2070	department issues under this section is valid for the lesser of:

S.B. 64

2071	(i) an amount of time that the recommending medical provider determines; or
2072	(ii) one year from the day the card is issued.
2073	(b)(i) A medical cannabis card that the department issues in relation to a terminal
2074	illness described in Section 26B-4-203 expires after one year.
2075	(ii) The recommending medical provider may revoke a recommendation that the
2076	provider made in relation to a terminal illness described in Section 26B-4-203 if
2077	the medical cannabis cardholder no longer has the terminal illness.
2078	(c) A medical cannabis card that the department issues in relation to acute pain as
2079	described in Section 26B-4-203 expires 30 days after the day on which the
2080	department first issues a conditional or full medical cannabis card.
2081	(6)(a) A medical cannabis patient card or a medical cannabis guardian card is renewable
2082	if:
2083	(i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a)
2084	or (b); or
2085	(ii) the cardholder received the medical cannabis card through the recommendation of
2086	the Compassionate Use Board under Section 26B-1-421.
2087	(b) The recommending medical provider who made the underlying recommendation for
2088	the card of a cardholder described in Subsection (6)(a) may renew the cardholder's
2089	card through phone or video conference with the cardholder, at the recommending
2090	medical provider's discretion.
2091	(c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
2092	shall pay to the department a renewal fee in an amount that:
2093	(i) subject to Subsection 26B-1-310(5), the department sets in accordance with
2094	Section 63J-1-504; and
2095	(ii) may not exceed the cost of the relatively lower administrative burden of renewal
2096	in comparison to the original application process.
2097	(d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
2098	patient card renews automatically at the time the minor's parent or legal guardian
2099	renews the parent or legal guardian's associated medical cannabis guardian card.
2100	(7)(a) A cardholder under this section shall carry the cardholder's valid medical
2101	cannabis card with the patient's name.
2102	(b)(i) A medical cannabis patient cardholder or a provisional patient cardholder may
2103	purchase, in accordance with this part and the recommendation underlying the
2104	card, cannabis in a medicinal dosage form, a cannabis product in a medicinal

2105	dosage form, or a medical cannabis device.
2106	(ii) A cardholder under this section may possess or transport, in accordance with this
2107	part and the recommendation underlying the card, cannabis in a medicinal dosage
2108	form, a cannabis product in a medicinal dosage form, or a medical cannabis
2109	device.
2110	(iii) To address the qualifying condition underlying the medical cannabis treatment
2111	recommendation:
2112	(A) a medical cannabis patient cardholder or a provisional patient cardholder may
2113	use medical cannabis or a medical cannabis device; and
2114	(B) a medical cannabis guardian cardholder may assist the associated provisional
2115	patient cardholder with the use of medical cannabis or a medical cannabis
2116	device.
2117	(8)(a) The department may revoke a medical cannabis card that the department issues
2118	under this section if:
2119	(i) the recommending medical provider withdraws the medical provider's
2120	recommendation for medical cannabis; or
2121	(ii) the cardholder:
2122	(A) violates this part; or
2123	(B) is convicted under state or federal law of, after March 17, 2021, a drug
2124	distribution offense.
2125	(b) The department may not refuse to issue a medical cannabis card to a patient solely
2126	based on a prior revocation under Subsection (8)(a)(i).
2127	(9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
2128	Administrative Rulemaking Act, a process to provide information regarding the
2129	following to an individual receiving a medical cannabis card:
2130	(a) risks associated with medical cannabis treatment;
2131	(b) the fact that a condition's listing as a qualifying condition does not suggest that
2132	medical cannabis treatment is an effective treatment or cure for that condition, as
2133	described in Subsection 26B-4-203(1); and
2134	(c) other relevant warnings and safety information that the department determines.
2135	(10) The department may establish procedures by rule, in accordance with Title 63G,
2136	Chapter 3, Utah Administrative Rulemaking Act, to implement the application and
2137	issuance provisions of this section.
2138	(11)(a) The department shall establish by rule, in accordance with Title 63G, Chapter 3,

2139	Utah Administrative Rulemaking Act, a process to allow an individual from another
2140	state to register with the department in order to purchase medical cannabis or a
2141	medical cannabis device from a medical cannabis pharmacy while the individual is
2142	visiting the state.
2143	(b) The department may only provide the registration process described in Subsection
2144	(11)(a):
2145	(i) to a nonresident patient; and
2146	(ii) for no more than two visitation periods per calendar year of up to 21 calendar
2147	days per visitation period.
2148	(12)(a) A person may submit to the department a request to conduct a research study
2149	using medical cannabis cardholder data that the state electronic verification system
2150	contains.
2151	(b) The department shall review a request described in Subsection (12)(a) to determine
2152	whether an institutional review board, as that term is defined in Section 26B-4-201,
2153	could approve the research study.
2154	(c) At the time an individual applies for a medical cannabis card, the department shall
2155	notify the individual:
2156	(i) of how the individual's information will be used as a cardholder;
2157	(ii) that by applying for a medical cannabis card, unless the individual withdraws
2158	consent under Subsection (12)(d), the individual consents to the use of the
2159	individual's information for external research; and
2160	(iii) that the individual may withdraw consent for the use of the individual's
2161	information for external research at any time, including at the time of application.
2162	(d) An applicant may, through the medical cannabis card application, and a medical
2163	cannabis cardholder may, through the state central patient portal, withdraw the
2164	applicant's or cardholder's consent to participate in external research at any time.
2165	(e) The department may release, for the purposes of a study described in this Subsection
2166	(12), information about a cardholder under this section who consents to participate
2167	under Subsection (12)(c).
2168	(f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of
2169	consent:
2170	(i) applies to external research that is initiated after the withdrawal of consent; and
2171	(ii) does not apply to research that was initiated before the withdrawal of consent.
2172	(g) The department may establish standards for a medical research study's validity, by

2173	rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
2174	Act.
2175	(13) The department shall record the issuance or revocation of a medical cannabis card
2176	under this section in the controlled substance database.
2177	Section 18. Section 26B-4-219 is amended to read:
2178	26B-4-219 . Pharmacy medical providers Registration Continuing education.
2179	(1)(a) A medical cannabis pharmacy:
2180	(i) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy
2181	Practice Act, as a pharmacy medical provider;
2182	(ii) may employ a physician who has the authority to write a prescription and is
2183	licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,
2184	Chapter 68, Utah Osteopathic Medical Practice Act, as a pharmacy medical
2185	provider;
2186	(iii) shall ensure that a pharmacy medical provider described in Subsection (1)(a)(i)
2187	works onsite during all business hours; and
2188	(iv) shall designate one pharmacy medical provider described in Subsection (1)(a)(i)
2189	as the pharmacist-in-charge to oversee the operation of and generally supervise
2190	the medical cannabis pharmacy.
2191	(b) The pharmacist-in-charge shall determine which cannabis and cannabis products the
2192	medical cannabis pharmacy maintains in the medical cannabis pharmacy's inventory.
2193	(c) An individual may not serve as a pharmacy medical provider unless the department
2194	registers the individual as a pharmacy medical provider in accordance with
2195	Subsection (2).
2196	(2)(a) The department shall, within 15 days after the day on which the department
2197	receives an application from a medical cannabis pharmacy on behalf of a prospective
2198	pharmacy medical provider, register and issue a pharmacy medical provider
2199	registration card to the prospective pharmacy medical provider if the medical
2200	cannabis pharmacy:
2201	(i) provides to the department:
2202	(A) the prospective pharmacy medical provider's name and address;
2203	(B) the name and location of the licensed medical cannabis pharmacy where the
2204	prospective pharmacy medical provider seeks to act as a pharmacy medical
2205	provider;
2206	(C) [a report detailing the completion of the continuing education requirement

2207	described in Subsection (2). I an estraculador ent that the individual has
2207	described in Subsection (3);] an acknowledgment that the individual has completed four hours of continuing education related to medical cannabis; and
	(D) evidence that the prospective pharmacy medical provider is a pharmacist who
2209	
2210	is licensed under Title 58, Chapter 17b, Pharmacy Practice Act, or a physician
2211	who has the authority to write a prescription and is licensed under Title 58,
2212	Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
2213	Osteopathic Medical Practice Act; and
2214	(ii) pays a fee to the department in an amount that, subject to Subsection 26B-1-310
2215	(5), the department sets in accordance with Section 63J-1-504.
2216	(b) The department may not register a recommending medical provider as a pharmacy
2217	medical provider.
2218	(3)(a) A pharmacy medical provider shall complete the continuing education described
2219	in this Subsection (3) in the following amounts:
2220	(i) as a condition precedent to registration, four hours; and
2221	(ii) as a condition precedent to renewal of the registration, four hours every two years.
2222	[(b) In accordance with Subsection (3)(a), the pharmacy medical provider shall:]
2223	[(i) complete continuing education:]
2224	[(A) regarding the topics described in Subsection (3)(d); and]
2225	[(B) offered by the department under Subsection (3)(c) or an accredited or
2226	approved continuing education provider that the department recognizes as
2227	offering continuing education appropriate for the medical cannabis pharmacy
2228	practice; and]
2229	[(ii) make a continuing education report to the department in accordance with a
2230	process that the department establishes by rule, in accordance with Title 63G,
2231	Chapter 3, Utah Administrative Rulemaking Act, and in collaboration with the
2232	Division of Professional Licensing and:]
2233	[(A) for a pharmacy medical provider who is licensed under Title 58, Chapter
2234	17b, Pharmacy Practice Act, the Board of Pharmacy; or]
2235	[(B) for a pharmacy medical provider licensed under Title 58, Chapter 67, Utah
2236	Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical
2237	Practice Act, the Medical Licensing Board.]
2238	[(c)] (b) The department may, in consultation with the Division of Professional
2239	Licensing, develop the continuing education described in this Subsection (3).
2240	[(d)] (c) The continuing education described in this Subsection (3) may discuss:

2241	(i) the provisions of this part;
2242	(ii) general information about medical cannabis under federal and state law;
2243	(iii) the latest scientific research on the endocannabinoid system and medical
2244	cannabis, including risks and benefits;
2245	(iv) recommendations for medical cannabis as it relates to the continuing care of a
2246	patient in pain management, risk management, potential addiction, and palliative
2247	care; or
2248	(v) best practices for recommending the form and dosage of medical cannabis based
2249	on the qualifying condition underlying a medical cannabis recommendation.
2250	(4)(a) A pharmacy medical provider registration card expires two years after the day on
2251	which the department issues or renews the card.
2252	(b) A pharmacy medical provider may renew the provider's registration card if the
2253	provider:
2254	(i) is eligible for a pharmacy medical provider registration card under this section;
2255	(ii) certifies to the department in a renewal application that the information in
2256	Subsection (2)(a) is accurate or updates the information;
2257	(iii) submits a report detailing the completion of the continuing education
2258	requirement described in Subsection (3); and
2259	(iv) pays to the department a renewal fee in an amount that:
2260	(A) subject to Subsection 26B-1-310(5), the department sets in accordance with
2261	Section 63J-1-504; and
2262	(B) may not exceed the cost of the relatively lower administrative burden of
2263	renewal in comparison to the original application process.
2264	(5)(a) Except as provided in Subsection (5)(b), a person may not advertise that the
2265	person or another person dispenses medical cannabis.
2266	(b) Notwithstanding Subsection (5)(a) and Section 4-41a-109, a registered pharmacy
2267	medical provider may advertise the following:
2268	(i) a green cross;
2269	(ii) that the person is registered as a pharmacy medical provider and dispenses
2270	medical cannabis; or
2271	(iii) a scientific study regarding medical cannabis use.
2272	(6)(a) The department may revoke a pharmacy medical provider's registration for a
2273	violation of this chapter.
2274	(b) The department may inspect patient records held by a medical cannabis pharmacy to

2275	ensure a pharmacy medical provider is practicing in accordance with this chapter and
2276	applicable rules.
2277	Section 19. Section 26B-4-222 is amended to read:
2278	26B-4-222 . Report.
2279	(1) By the November interim meeting each year, the department shall report to the Health
2280	and Human Services Interim Committee on:
2281	(a) the number of applications and renewal applications filed for medical cannabis cards;
2282	(b) the number of qualifying patients and designated caregivers;
2283	(c) the nature of the debilitating medical conditions of the qualifying patients;
2284	(d) the age and county of residence of cardholders;
2285	(e) the number of medical cannabis cards revoked;
2286	(f) the number of practitioners providing recommendations for qualifying patients; and
2287	[(g) the number of license applications and renewal license applications received;]
2288	[(h) the number of licenses the department has issued in each county;]
2289	[(i) the number of licenses the department has revoked;]
2290	[(j) the quantity of medical cannabis shipments that the state central patient portal
2291	facilitates;]
2292	[(k) the number of overall purchases of medical cannabis and medical cannabis
2293	products from each medical cannabis pharmacy;]
2294	[(1)] (g) the expenses [incurred-]and revenues [generated from the medical cannabis
2295	program] of the Qualified Patient Enterprise Fund created in Section 26B-1-310[; and] .
2296	[(m) an analysis of product availability in medical cannabis pharmacies in consultation
2297	with the Department of Agriculture and Food.]
2298	(2) The report shall include information provided by the Center for Medical Cannabis
2299	Research described in Section 53B-17-1402.
2300	(3) The department may not include personally identifying information in the report
2301	described in this section.
2302	(4) The department shall report to the working group described in Section 36-12-8.2 as
2303	requested by the working group.
2304	Section 20. Effective Date.
2305	This bill takes effect on May 7, 2025.